Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

10-20-2020

Pediatric Life Support: 2020 International Consensus on
Cardiopulmonary Resuscitation and Emergency Cardiovascular
Care Science With Treatment Recommendations
Ian K. Maconochie
Richard Aickin
Mary Fran Hazinski
Dianne L. Atkins
Robert Bingham

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Maconochie, Ian K.; Aickin, Richard; Hazinski, Mary Fran; Atkins, Dianne L.; Bingham, Robert; Couto,
Thomaz Bittencourt; Guerguerian, Anne Marie; Nadkarni, Vinay M.; Ng, Kee Chong; Nuthall, Gabrielle A.;
Ong, Gene Y.K.; Reis, Amelia G.; Schexnayder, Stephen M.; Scholefield, Barnaby R.; Tijssen, Janice A.;
Nolan, Jerry P.; Morley, Peter T.; Van de Voorde, Patrick; Zaritsky, Arno L.; and de Caen, Allan R., "Pediatric
Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency
Cardiovascular Care Science With Treatment Recommendations" (2020). Paediatrics Publications. 2305.
https://ir.lib.uwo.ca/paedpub/2305

Authors
Ian K. Maconochie, Richard Aickin, Mary Fran Hazinski, Dianne L. Atkins, Robert Bingham, Thomaz
Bittencourt Couto, Anne Marie Guerguerian, Vinay M. Nadkarni, Kee Chong Ng, Gabrielle A. Nuthall, Gene
Y.K. Ong, Amelia G. Reis, Stephen M. Schexnayder, Barnaby R. Scholefield, Janice A. Tijssen, Jerry P.
Nolan, Peter T. Morley, Patrick Van de Voorde, Arno L. Zaritsky, and Allan R. de Caen

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/2305

Circulation

Pediatric Life Support
2020 International Consensus on Cardiopulmonary Resuscitation
and Emergency Cardiovascular Care Science With Treatment
Recommendations

Downloaded from http://ahajournals.org by on June 22, 2022

ABSTRACT: This 2020 International Consensus on Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care Science With
Treatment Recommendations (CoSTR) for pediatric life support is
based on the most extensive evidence evaluation ever performed
by the Pediatric Life Support Task Force. Three types of evidence
evaluation were used in this review: systematic reviews, scoping
reviews, and evidence updates. Per agreement with the evidence
evaluation recommendations of the International Liaison Committee
on Resuscitation, only systematic reviews could result in a new or
revised treatment recommendation.
Systematic reviews performed for this 2020 CoSTR for pediatric life
support included the topics of sequencing of airway-breaths-compressions
versus compressions-airway-breaths in the delivery of pediatric basic life
support, the initial timing and dose intervals for epinephrine administration during resuscitation, and the targets for oxygen and carbon dioxide
levels in pediatric patients after return of spontaneous circulation. The
most controversial topics included the initial timing and dose intervals of
epinephrine administration (new treatment recommendations were made)
and the administration of fluid for infants and children with septic shock
(this latter topic was evaluated by evidence update). All evidence reviews
identified the paucity of pediatric data and the need for more research
involving resuscitation of infants and children.
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T

he 2020 International Consensus on Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC) Science With Treatment
Recommendations (CoSTR) is the fourth in a series
of annual publications from the International Liaison
Committee on Resuscitation (ILCOR). This 2020 CoSTR
summary for pediatric life support (PLS) includes new
topics addressed by Systematic Reviews (SysRevs) performed within the past 12 months. It also includes
updates of the PLS CoSTR statements published from
2010 through 2019 as needed, based on additional
evidence evaluations. As a result, this 2020 CoSTR
summary for PLS is the most comprehensive update
S142 October 20, 2020
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since 2010. The 3 major types of evidence evaluation
supporting this 2020 publication are the SysRev, the
Scoping Review (ScopRev), and the Evidence Update
(EvUp).
Topics and types of reviews were prioritized by the PLS
Task Force over the past 12 months on the basis of task
force consensus that the answers to the review questions were critical, task force expert awareness of recent
studies on the topics that could change treatment recommendations, and input and requests from the ILCOR
member councils. SysRevs were performed on topics if
deemed critical on the basis of the questions involved or
if publication of studies suggested the need to consider
new or modified treatment recommendations. ScopRevs
and EvUps were performed if the task force or member
councils identified a topic as important or if it had not
been reviewed in several years; ScopRevs and EvUps were
intended to determine if sufficient published evidence existed to suggest the need for a SysRev.
The SysRev is a rigorous process following strict
methodology to answer a specific question, and each
of these ultimately resulted in the generation of a task
force CoSTR included in this summary. The SysRevs
were performed by a knowledge synthesis unit, an
expert systematic reviewer, or the PLS Task Force, and
many resulted in separate SysRevs publications.
To begin the SysRev, the question to be answered was
phrased in terms of the PICOST (population, intervention, comparator, outcome, study design, time frame)
format. The methodology used to identify the evidence
was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).1 The approach used to evaluate the evidence was based on that
proposed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) working
group.2 Using this approach, the PLS Task Force rated
as high, moderate, low, or very low the certainty/confidence in the estimates of effect of an intervention or assessment across a body of evidence for each of the predefined outcomes. Randomized controlled trials (RCTs)
generally began the analysis as high-certainty evidence,
and observational studies generally began the analysis
as low-certainty evidence; examination of the evidence
using the GRADE approach could result in downgrading
or upgrading the certainty of evidence. For additional
information, refer to “Evidence Evaluation Process and
Management of Potential Conflicts of Interest.”3,3a
When a pre-2015 CoSTR treatment recommendation was not updated, the language used in the recommendation differed from that used in the GRADE approach because GRADE was not used before 2015.4–6
Draft 2020 (ie, new) CoSTRs for PLS were posted on
the ILCOR website7 for public comment between March
26, 2018, and January 10, 2020. The draft CoSTR statements were viewed 31 468 times with 16 comments
received. All comments were discussed by the PLS Task
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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Force and modifications made as needed to the content
or to the recommendations for future search strategies.
This summary contains the final wording of the CoSTR
statements as approved by the ILCOR PLS Task Force and
the ILCOR member councils after review and consideration of comments posted online in response to the draft
CoSTRs. In this publication, each topic includes the PICOST as well as the CoSTR, an expanded Justification and
Evidence to Decision Framework Highlights section, and a
list of knowledge gaps requiring future research studies.
An evidence-to-decision table is included for each CoSTR
in Appendix A in the Supplemental Materials.
The second major type of evidence evaluation performed to support this 2020 CoSTR summary for PLS is
a ScopRev. ScopRevs are designed to identify the extent,
range, and nature of evidence on a topic or question,
and they were performed by topic experts in consultation with the PLS Task Force. The task force analyzed the
identified evidence and determined its value and implications for resuscitation practice or research. The rationale
for the ScopRev, the summary of evidence, and task force
insights—all are highlighted in the body of this publication. Any previous treatment recommendations are reiterated. The task force noted whether the ScopRev identified substantive evidence that could result in a change
in the ILCOR treatment recommendations. If sufficient
evidence was identified, the task force suggested consideration of a (future) SysRev to support the development
of an updated CoSTR. All ScopRevs are included in their
entirety in Appendix B in the Supplemental Materials.
The third type of evidence evaluation supporting this
2020 CoSTR for PLS is an EvUp. EvUps were generally
performed to identify new studies published after the
most recent ILCOR evidence evaluation, typically by
using search terms and methodologies from previous
reviews. These EvUps were performed by task force
members, collaborating experts, or members of council
writing groups. The EvUps are cited in the body of this
publication with a note as to whether the evidence suggested the need to consider a SysRev; the most recent
ILCOR treatment recommendation was reiterated.
In this publication, no change in an ILCOR treatment
recommendation resulted from a ScopRev or an EvUp; if
substantial new evidence was identified, the task force
recommended consideration of a SysRev. All EvUps are
included in Appendix C in the Supplemental Materials,
as they were drafted by the reviewers.
Note: The reviews and treatment recommendations
apply to infants (28 days to 12 months) and children
(the age definitions varied in the cited studies). Evidence
evaluation of studies of resuscitation of newborns (especially at birth) can be found in “Neonatal Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
Science With Treatment Recommendations”7a,7b in this
supplement.
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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TOPICS REVIEWED IN THIS 2020 PLS
CoSTR
Note: As indicated above, the PLS CoSTR evidence reviews were all completed by January 10, 2020. As a result, this document does not address the topic of potential influence of coronavirus disease 2019 (COVID-19)
on resuscitation practice. In the spring of 2020, an ILCOR writing group was assembled to identify and evaluate the published evidence regarding risks of aerosol
generation and infection transmission during attempted
resuscitation of adults, children, and infants. This group
developed a consensus on science with treatment recommendations and task force insights. This statement
is published as a separate document.8 As new evidence
emerges, the ILCOR task forces will review and update
this statement, so the reader is referred to the ILCOR
website7 for the most up-to-date recommendations.
Pediatric Basic Life Support (PBLS): CPR and CPR
Quality
• Sequence of compression and ventilation (BLS
661: Shared SysRev)
• Pulse check accuracy (PLS 393: EvUp)
• Chest compression–only versus conventional CPR
(2017 CoSTR)
• Pediatric compression depth (PLS 314: ScopRev)
• 1-hand versus 2-hand compressions for children
(PLS 375: EvUp) combined with circumferential
compressions for infants (PLS 416: EvUp)
PBLS: Automated External Defibrillation
• Use of automated external defibrillators (AEDs) for
infants with out-of-hospital cardiac arrest (OHCA)
(PLS 425: EvUp)
PBLS: Prevention of Cardiac Arrest
• Pediatric early-warning scores (PEWS) (PLS 818:
ScopRev)
• Pediatric medical emergency/rapid response teams
(PLS 397: EvUp)
Pediatric Advanced Life Support (PALS): Recognition and Treatment of Septic Shock
• Fluid administration for the child with septic shock
(PLS 1534: EvUp)
• Vasoactive drugs for septic shock (PLS 1604:
ScopRev)
• Corticosteroids for pediatric septic shock (PLS 413:
EvUp)
PALS: Recognition and Prearrest Treatments for
Shock
• Graded volume resuscitation for traumatic/hemorrhagic shock (PLS 400: ScopRev)
• Timing of intubation for shock (PLS 399: EvUp)
• Prearrest care of the infant or child with dilated
cardiomyopathy or myocarditis (PLS 819: EvUp)
• Cardiogenic shock and inotropes (PLS 418: EvUp)
October 20, 2020
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PALS: Management of Deterioration With Pulmonary Hypertension
• Prevention and management of pulmonary hypertensive crises in infants and children (PLS 391: EvUp)
• Opioids, sedatives, and neuromuscular blocking
drugs for pulmonary hypertension (PLS New: EvUp)
• Therapy with inhaled nitric oxide or prostaglandin
I2 for pulmonary hypertensive crisis and right heart
failure (PLS New: EvUp)
PALS: Recognition and Treatment of Nonarrest
Arrhythmias
• Drugs for supraventricular tachycardia (PLS 379: EvUp)
• Treatment for unstable ventricular tachycardia (PLS
409: EvUp)
• CPR for heart rate of less than 60/min (PLS 1535: EvUp)
• Drugs for the treatment of bradycardia: Atropine
versus no atropine and atropine versus epinephrine (PLS New: EvUp)
• Emergency transcutaneous pacing for bradycardia
(PLS New: EvUp)
• Channelopathies (PLS 417: EvUp)

Downloaded from http://ahajournals.org by on June 22, 2022

PALS: Manual Defibrillation
• Pad size, type, and placement for pediatric defibrillation (PLS 378 and PLS 043: EvUp)
• Energy doses for defibrillation (PLS 405: ScopRev)
• Single or stacked shocks for pediatric defibrillation
(PLS 389: EvUp)
PALS: Airways, Oxygenation, and Ventilation
• Ventilation rate when a perfusing rhythm is present (PLS 3103A and PLS 382: EvUp)
• Oxygen concentration during cardiac arrest (PLS
396: ScopRev)
• Ventilation during CPR with bag and mask compared with an advanced airway (2019 CoSTR)
• Use of cuffed or uncuffed tracheal tubes (PLS 412:
EvUp)
• Atropine for emergency intubation (PLS 821: EvUp)
• Cricoid pressure during intubation (PLS 376: EvUp)
• Use of devices to verify advanced airway placement (PLS 385: EvUp)
• Ventilation rate with advanced airway during cardiac arrest (PLS 3103A and PLS 382: EvUp)
PALS: Circulatory Support During CPR
• Extracorporeal CPR for in-hospital cardiac arrest
(2019 CoSTR)
PALS: Physiological Monitoring During Arrest to
Guide Therapy and/or Intra-arrest Prognostication
• Invasive blood pressure monitoring during CPR
(PLS 826: ScopRev)
• Use of near-infrared spectroscopy (NIRS) during
cardiac arrest (PLS New: ScopRev)
• Bedside ultrasound to identify perfusing rhythm
(PLS 408: ScopRev)
S144 October 20, 2020
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• End-tidal CO2 monitoring during CPR (PLS 827:
ScopRev)
PALS: Resuscitation Drug Administration and
Timing
• Methods of calculating pediatric drug doses (PLS
420: EvUp)
• Intraosseous (IO) versus intravenous (IV) route of
drug administration (PLS, neonatal life support
[NLS], and advanced life support [ALS]: SysRev)
• Epinephrine time of initial dose and dose interval
during CPR (PLS 1541: SysRev)
• Amiodarone versus lidocaine for shock-resistant
ventricular fibrillation or pulseless ventricular
tachycardia (2018 CoSTR)
• Sodium bicarbonate administration for children in
cardiac arrest (PLS 388: EvUp)
• Calcium administration in children (PLS 421: EvUp)
PALS: Special Resuscitation Situations—Septic
Shock, Congenital Heart Disease, and Trauma
• Resuscitation of the child with septic shock (PLS
1534: EvUp)
• Resuscitation of the patient with a single ventricle
(PLS 390: EvUp)
• Resuscitation of the patient with hemi-Fontan or
Fontan circulation (PLS 392: EvUp)
• Resuscitation after traumatic arrest (PLS 498: EvUp)
PALS: Post–Cardiac Arrest Care, Including
Postarrest Prognostication
• Targeted temperature management (2019 CoSTR)
• Oxygen and carbon dioxide targets in pediatric
patients with return of spontaneous circulation
(ROSC) after cardiac arrest (PLS 815: SysRev)
• Post-ROSC blood pressure control (PLS 820: EvUp)
• Post-ROSC neuro-prognostication and use of electroencephalogram (PLS 813 and PLS 822: EvUp)

PBLS: CPR AND CPR QUALITY
The PBLS topics in this section include the optimal sequence of compressions and ventilation, pulse check
accuracy, compression-only compared with conventional CPR, the optimal depth of chest compressions, and
1-hand versus 2-hand chest compressions for children
and circumferential chest compressions for infants.

Sequence of Compression and
Ventilation (BLS 661: Shared SysRev)
The PLS Task Force last reviewed the sequence of pediatric BLS in 2015.9,10 In 2020, the BLS Task Force performed a SysRev on the topic (see the Starting CPR
section [BLS 661: SysRev] of the BLS publication in this
supplement). This SysRev search included adults and
children in all settings. Refer to the BLS publication
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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for details of the evidence summary and task force
considerations.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Adults and children with OHCA
• Intervention: Commencing CPR beginning with
compressions first (30:2)
• Comparator: CPR beginning with ventilation first
(2:30)
• Outcome: Survival with favorable neurological /
functional outcome at discharge, 30 days, 60 days,
180 days, and/or 1 year; survival only at discharge,
30 days, 60 days, 180 days, and/or 1 year; and
ROSC
• Study design: RCTs and nonrandomized studies
(nonrandomized controlled trials [non-RCTs], interrupted time series, controlled before-and-after
studies, cohort studies) eligible for inclusion
• Time frame: All languages were included if there
was an English abstract. The literature search was
updated in September 2019.

Downloaded from http://ahajournals.org by on June 22, 2022

Summary of Evidence
The 2020 PLS ScopRev did not identify any new human
pediatric evidence about sequencing for initiating CPR
published after the 2015 CoSTR.11,12
As a result, the recommendations for sequencing
of BLS steps for infants and children in cardiac arrest
remain unchanged from those published in 2015 (see
Treatment Recommendations), with insufficient evidence to make a recommendation. To review the entire
SysRev for adult data, see the Starting CPR section [BLS
661: SysRev] of the BLS publication in this supplement.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2015.11,12
The confidence in effect estimates is so low that
the panel decided that a recommendation was too
speculative.

Pulse Check Accuracy (PLS 393: EvUp)
This EvUp was performed to identify studies after the
review about pulse check accuracy in 2010.9,10 Studies
about the accuracy of pulse check versus assessment of
signs of life were insufficient to identify cardiac arrest,
and the task force agreed that there is no need to suggest consideration of a SysRev. As a result, the 2010
treatment recommendation is unchanged.9,10 To review
the EvUp, see Supplement Appendix C-1.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in cardiac arrest
• Intervention: Use of pulse check
• Comparator: Assessment of signs of life
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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• Outcome: Improve accuracy of diagnosis of pediatric cardiopulmonary arrest
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and all languages were
included if there was an English abstract. Literature
was updated in December 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
Palpation of a pulse (or its absence) is not reliable
as the sole determinant of cardiac arrest and need for
chest compressions. If the victim is unresponsive, and
not breathing normally, and there are no signs of life,
lay rescuers should begin CPR.
In infants and children with no signs of life, healthcare providers should begin CPR unless they can definitely palpate a pulse within 10 seconds.

Chest Compression–Only Versus
Conventional CPR (2017 CoSTR)
In 2017, a SysRev13 and an ILCOR Pediatric CoSTR14,15
were published on the topic of compression-only CPR
compared with conventional CPR for infants and children. Refer to those publications for details of the evidence summary and task force considerations.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Patients of all ages (ie, neonates, children, adults) with cardiac arrest from any cause
and across all settings (in-hospital and out-of-hospital); studies that included animals not eligible
• Intervention: All manual CPR methods including
compression-only CPR, continuous compression
CPR, and CPR with different compression-toventilation ratios. Compression-only CPR included
continuous delivery of compressions with no ventilation; continuous chest compression CPR included
compression with asynchronous ventilation or
minimally interrupted cardiac resuscitation. Studies
that mentioned the use of a mechanical device during CPR were considered only if the same device
was used across all relevant intervention arms and
would therefore not confound the observed effect.
• Comparator: Studies had to compare at least 2
different CPR methods from the eligible interventions; studies without a comparator were excluded
• Outcome: The primary outcome was favorable
neurological outcomes, evaluated by cerebral performance scale or a modified Rankin Scale score;
secondary outcomes were survival, ROSC, and
quality of life
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• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion; study designs without a comparator group (eg, case series, cross-sectional studies),
reviews, and pooled analyses excluded
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated in December 2019.
Treatment Recommendations
These treatment recommendations are unchanged
from 2017.14,15
We suggest that bystanders provide CPR with ventilation for infants and children younger than 18 years
with OHCA (weak recommendation, very low-quality
evidence).
We recommend that if bystanders cannot provide
rescue breaths as part of CPR for infants and children
younger than 18 years with OHCA, they should at least
provide chest compressions (good practice statement).

Pediatric Compression Depth (PLS 314:
ScopRev)

Downloaded from http://ahajournals.org by on June 22, 2022

Rationale for Review
The most recent (2015) PLS review11,12 about pediatric
chest compression depth was based on a SysRev that
identified 2 observational pediatric studies.16,17 There is
now greater availability of CPR feedback devices providing real-time data about the specific targets for components of CPR, including depth of compression; studies
in adults18,19 demonstrated that overcompression can
cause harm. The ScopRev was undertaken to determine
the extent of current available evidence about the effectiveness of various compression depths used during
resuscitation of infants and children. For details of the
ScopRev, see Supplement Appendix B-1.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children who had received
chest compressions after out-of-hospital or in-hospital cardiac arrest (excluding newborn children)
• Intervention: Any specific chest compression depth
• Comparator: Depth specified in 2017 CoSTR
publication14,15
–	At least one third the AP [anteroposterior] chest
depth
–	Approximately 1½ inches (4 cm) in infants, 2
inches (5 cm) in children
• Outcome:
–	Short-term survival and neurological outcomes
(eg, ROSC, hospital discharge, 28 days, 30 days,
and 1 month)
–	Long-term survival and neurological outcomes
(eg, 3 months, 6 months, and 1 year)
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• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The search was
updated to October 2019.
Summary of Evidence
No new published evidence was identified with this
ScopRev. The PLS Task Force did identify an ongoing large
prospective observational international multicenter study
on CPR quality using dual-sensor CPR feedback devices.20
The results of this study, once published, may help address the impact of chest compression depth on CPR outcomes. The task force concluded that there is no need
to recommend a new SysRev at this time, and the decision will be reconsidered following the publication of any
relevant studies. For this 2020 CoSTR update, the 2015
treatment recommendations11,12 are unchanged.
Task Force Insights
The PLS Task Force recognized the paucity of pediatric
studies and substantial identified gaps in the pediatric literature about chest compression depth (eg, the absence of
data on the impact of overcompression). Previous studies
used feedback devices with a single displacement sensor/
accelerometer; these are notably unreliable because the
compression depth they measure can be affected by the
type of surface on which the compressions are performed;
overestimation of compression depth occurs if the surface
on which the patient rests (eg, bed or trolley mattress) enables movement even if a CPR board is used. Chest compression depth studies using feedback devices with dual
displacement sensors/accelerometers may improve the accuracy of measurement of compression depth.
Treatment Recommendations
These treatment recommendations are unchanged
from 2015.11,12
We suggest that rescuers compress an infant’s chest
by at least one third the anteroposterior dimension, or
approximately 1½ inches (4 cm). We suggest that rescuers compress a child’s chest by at least one third the
anteroposterior dimension, or approximately 2 inches (5
cm) (weak recommendation, very low-quality evidence).

One-Hand Versus 2-Hand Compressions
for Children (PLS 375: EvUp) Combined
With Circumferential Compressions for
Infants (PLS 416: EvUp)
An EvUp was performed to identify the available evidence about different techniques for chest compressions for infants and children. The previous review
was published in 2010.9,10 The EvUp did identify several studies published after 2010, and the task force
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agreed that these studies suggest the need to consider
requesting a SysRev. Until a new SysRev is completed
and analyzed by the PLS Task Force, the 2010 treatment
recommendation remains in effect. To review the EvUp,
see Supplement Appendix C-2.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in cardiac arrest
in any setting
• Intervention: 2 hands, 1 hand, circumferential, 2
fingers, a specific other method, a specific location
• Comparator: Another method or location
• Outcome: Any
• Study design: RCTs and nonrandomized studies (nonRCTs, interrupted time series, controlled before-andafter studies, cohort studies) eligible for inclusion
• Time frame: All years and languages were included
if there was an English abstract. Literature was
searched to December 2019.

Downloaded from http://ahajournals.org by on June 22, 2022

Treatment Recommendation
This treatment recommendation (below) is unchanged
from 2010.9,10
Either a 1-hand or a 2-hand technique can be used
for performing chest compressions on children.
There are insufficient data to make a recommendation
for or against the need for a circumferential squeeze of
the chest when performing the 2 thumb–encircling hands
technique of external chest compression for infants.

PBLS: AUTOMATED EXTERNAL
DEFIBRILLATION
Use of Automated External Defibrillators
for Infants With Out-of-Hospital Cardiac
Arrest (PLS 425: EvUp)
An EvUp was performed to determine if there were
any published studies about the use of AEDs for infants
with OHCA. The EvUp identified insufficient evidence
to justify a SysRev or suggest the need for a change to
the 2010 treatment recommendation; as a result, the
2010 treatment recommendation is unchanged.9,10 To
review the EvUp, see Supplement Appendix C-3.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in cardiac arrest
in any setting
• Intervention: Use of an automated external defibrillators at a certain moment in the algorithm
• Comparator: At another moment in the algorithm
or not using an automated external defibrillator or
using an automated external defibrillator with a
dose attenuator
• Outcome: Any
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• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. Literature was
searched to December 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
For treatment of out-of-hospital ventricular fibrillation (VF)/pulseless ventricular tachycardia (pVT) in infants, the recommended method of shock delivery by
device is listed in order of preference below. If there
is any delay in the availability of the preferred device,
the device that is available should be used. The AED algorithm should have demonstrated high specificity and
sensitivity for detecting shockable rhythms in infants.
The order of preference is as follows:
1. Manual defibrillator
2. AED with dose attenuator
3. AED without dose attenuator

PBLS: PREVENTION OF CARDIAC
ARREST
Pediatric Early-Warning Scores (PLS 818:
ScopRev)
Rationale for Review
The topic was selected for review because the task force
was aware of several recent relevant publications, including SysRevs, a ScopRev, and a large-scale RCT published
after the most recent (2015) CoSTR on the topic.11,12
PEWS are tools that evaluate clinical presentation
risk of clinical deterioration.
See Supplement Appendix B-2.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in a hospital
setting
• Intervention: PEWS with or without rapid response
teams/medical emergency teams
• Comparator: No PEWS with or without rapid
response teams or medical emergency teams
• Outcome: In-hospital deterioration, including
mortality
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract; unpublished studies (eg, conference abstracts, trial protocols) were
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excluded. The literature search was updated to
September 15, 2019.
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Summary of Evidence
We identified 3 SysRevs21–23 and 1 ScopRev24 published
after 2015; all noted the limited evidence for the usefulness of PEWS for preventing physiological deterioration and improving clinical outcomes.
The Evaluating Processes of Care and the Outcomes
of Children in Hospital (EPOCH) study was published in
2018. This was an international cluster RCT of 21 hospitals enrolling patients from birth (gestational age 37
weeks or more) up to 18 years of age.25 This study included all-cause mortality as a primary outcome and as
a secondary outcome a composite outcome reflecting
late critical care admission. Ten hospitals implemented a
bedside PEWS system compared with usual care (ie, did
not use a severity early-warning score) in 11 hospitals.
This was one of the largest studies of its kind, involving
144 539 patient discharges with 559 443 patient days
and 144 539 patients in total completing the trial.
There was no significant reduction in all-cause mortality when the use of bedside PEWS was compared
with standard care (1.93 per 1000 patient discharges
compared with 1.56 per 1000 patient discharges; adjusted odds ratio [OR], 1.01; 95% CI, 0.61–1.69). The
prevalence of significant clinical deterioration events
was lower (0.5 per 1000 patient days compared with
0.84 per 1000 patient days) at hospitals using bedside
PEWS compared with usual care hospitals (adjusted
rate ratio 0.77 [95% CI, 0.61–0.97]).
The EPOCH authors concluded that their findings did
not support the use of PEWS to reduce mortality.25
The PLS draft ScopRev was posted on the ILCOR website and was viewed 345 times without any comments
that addressed the need for a SysRev on this topic. To
review the ScopRev, see Supplement Appendix B-2.
Task Force Insights
The PLS Task Force concluded that the implementation
of PEWS should be part of an overall clinical response
system, with the task force placing a higher value on
improving healthcare provider ability to recognize and
intervene for patients with deteriorating illness over the
expense incurred by a healthcare system committing
significant resources to implement PEWS. The task force
also noted that the complex process of optimizing patient care is likely to include both the implementation of
PEWS and ongoing healthcare provider education. The
PLS Task Force agreed that the decision to use PEWS
should be balanced between use of existing resources
and capabilities of the healthcare setting to adapt to its
use and the consequences of its use.
In the PEWS studies, mortality is a common outcome marker. However, the incidence of cardiac arrest
is low (especially outside the critical care setting), so
the incidence of significant clinical deterioration is an
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additional important outcome in determining sample
sizes for such studies.
The PLS Task Force agreed that there is a need to
request a SysRev. Until completion of the SysRev, the
2015 treatment recommendations remain in effect.11,12
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2015.11,12
The confidence in the estimate of predictive value is
so low that the panel decided that a recommendation
is too speculative.

Pediatric Medical Emergency/Rapid
Response Teams (PLS 397: EvUp)
Rapid response teams (RRTs) are hospital teams that
are activated to evaluate and respond to patients at
risk for clinical deterioration. The topic of medical
emergency teams (METs)/RRTs was last reviewed in
2015.11,12 This EvUp was requested to identify relevant
evidence on the topic published after that date. Two
preintervention/postintervention studies demonstrated a decrease in the number of resuscitation events,
although there was no clear decrease in mortality. One
observational registry study demonstrated no change
in the mortality rate beyond that which was already
expected from the preimplementation trends. This
finding is not significantly different from the 2015 review. To review the EvUp, see Supplement Appendix
C-4. There is no indication to change the 2015 CoSTR
recommendation.
Treatment Recommendation
This treatment recommendation (below) is unchanged
from 2015.11,12
We suggest the use of pediatric MET/RRT systems
in hospitals that care for children (weak recommendation, very low-quality evidence). In making this recommendation, we place a higher value on the potential to
recognize and intervene for patients with deteriorating
illness over the expense incurred by a healthcare system
committing significant resources to implement a MET/
RRT system. We recognize that the decision to use a
MET/RRT system should be balanced by the existing resources and capabilities of the institution.

PALS: RECOGNITION AND TREATMENT
OF SEPTIC SHOCK
Fluid Administration for the Child With
Septic Shock (PLS 1534: EvUp)
Note: This topic was prioritized for review because the
approach to the management of fluid resuscitation in
infants and children with septic shock is changing as
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a result of recent published evidence. The summary of
this EvUp is more detailed than for other EvUps owing to the critical nature of these new findings and
in acknowledgment of the 2020 publication of new
guidelines for the management of infants and children
with septic shock.26
This topic was last reviewed in 2015,11,12 when the
evidence evaluation included fluid administration for
shock associated with dengue fever and malaria. This
EvUp looked specifically at the impact of different fluid
regimens in infants and children with septic shock but
excluded studies of shock associated with dengue or
malaria because the pathophysiology of shock with
those conditions is atypical when compared with septic
shock associated with other causes. The role of fluid administration in shock associated with dengue or malaria
will be considered in future reviews.
This draft EvUp can be viewed in Supplement Appendix C-5 because it is only outlined here in the main
body of text. Among the 12 studies in the final evidence review were 3 RCTs27–29 and 3 SysRevs.30–32 In addition, the EvUp identified 1 RCT33 that did not directly
address the PICO (population, intervention, comparator, outcome) question but provided information about
the effect of a fluid bolus on pediatric cardiac index.
The EvUp also analyzed the results of 4 nonrandomized
studies34–37 and 1 study protocol.38
The Society of Critical Care Medicine’s Surviving
Sepsis Campaign International Guidelines for the
Management of Septic Shock and Sepsis-Associated
Organ Dysfunction in Children was published in February 2020,26 immediately before the submission of
this publication. In these 2020 surviving sepsis guidelines, recommendations for fluid administration differ
based on the availability of intensive care within the
system caring for the infant or child. For systems with
the availability of intensive care, the authors suggest
the administration of 10 to 20 mL/kg boluses, up to a
total of 40 to 60 mL/kg in the first hour, to be titrated
to the patient’s response and to be discontinued if
the signs of fluid overload develop. If hypotension is
present in systems without the availability of intensive care, the authors suggest the administration of
10 to 20 mL/kg boluses, up to a total of 40 mL/kg in
the first hour (also titrated to response and discontinued if signs of fluid overload develop). If the infant
or child is not hypotensive and is in a system without
the availability of intensive care, the authors recommend against bolus fluid administration but to start
maintenance fluids.26
The PLS Task Force agreed that a new SysRev is
needed to reevaluate the evidence and modify the
2015 PLS treatment recommendations as needed. Until the SysRev is completed and analyzed by the task
force, the 2015 treatment recommendations remain in
effect.11,12
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children who are in septic
shock in any setting
• Intervention 1: Use of restrictive volume of resuscitation fluid (less than 20 mL/kg)
• Comparator 1: Nonrestrictive volume (20 mL/kg or
greater) or the use of noncrystalloid fluids
• Intervention 2: Use of noncrystalloid fluids
• Comparator 2: Use of crystalloid fluids
• Intervention 3: Use of balanced crystalloid solution
(eg, Ringer’s lactate)
• Comparator 3: Use of unbalanced isotonic crystalloid solution (normal saline)
• Outcome: Survival to hospital discharge, need for
mechanical ventilation, need for vasopressor support, complications, time to resolution of shock,
hospital length of stay, ventilator-free days, or total
IV fluids administered
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and all languages were
included if there was an English abstract. The literature search was from January 2015 to January 2020.
Treatment Recommendations
These treatment recommendations are unchanged
from 2015.11,12
We suggest using an initial fluid bolus of 20 mL/kg
for infants and children with shock, with subsequent
patient reassessment, for patients with the following
disease states:
• Severe sepsis (weak recommendation, low-quality
evidence)
• Severe malaria (weak recommendation, low-quality evidence)*
• Dengue shock syndrome (weak recommendation,
low-quality evidence)*
We suggest against the routine use of bolus intravenous fluids (crystalloids or colloids) for infants and children with a “severe febrile illness” who are not in shock
(weak recommendation, low-quality evidence).*
Reassessment, regardless of therapy administered,
should be emphasized so that deterioration is detected
at an early stage.

Vasoactive Drugs for Septic Shock (PLS
1604: ScopRev)
Rationale for Review
Although pediatric septic shock is associated with significant mortality/morbidity, substantial progress has
*These populations were included in the 2015 CoSTR but not the 2020 EvUp.
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been made in improving the recognition of septic shock
and the development of bundles of care aimed at bettering patient outcomes. The most recent review of vasoactive drugs (labeled “inotropes and vasopressors”)
for septic shock was published in 2010.9,10 That CoSTR
considered all forms of distributive shock, whereas this
ScopRev looked specifically at the use of vasoactive
drugs in pediatric septic shock, excluding other forms
of distributive shock. This ScopRev looked at comparative studies of 1 vasoactive drug with another. To review
the ScopRev, see Supplement Appendix B-3.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with septic shock,
with and without myocardial dysfunction
• Intervention: Use of any specific vasoactive drug
• Comparator: Standard care
• Outcome: Improved patient outcomes (hemodynamics, survival)
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was from 1946 to November 2019.
Downloaded from http://ahajournals.org by on June 22, 2022

Summary of Evidence
The ScopRev identified 2 relevant RCTs. The first39 included 60 children with septic shock in emergency departments or critical care units and compared the effects
of dopamine with those of epinephrine. The primary
outcome was resolution of shock in the first hour, which
was more likely to occur among those receiving epinephrine rather than dopamine (OR, 4.8; 95% CI, 1.3–
17.2; P=0.019). On day 3, there were lower sequential
organ failure assessment scores (ie, less derangement) in
the epinephrine group (8 versus 12, P=0.05). There was
no difference in the adverse event rate (16.1% versus
13.8%, P=0.8) and no difference in mortality, although
this study was not powered for mortality.
The second study40 was a double-blind RCT that evaluated 120 children with refractory septic shock (despite
the administration of 40 mL/kg of fluid). Randomization was to either dopamine or epinephrine, with the
primary outcome of 28-day mortality and the secondary outcome of healthcare-associated infection. Dopamine administration was linked with an increased risk of
death and healthcare-associated infection in comparison with epinephrine administration. The PLS Task Force
members were concerned that the doses of epinephrine
would have produced a disproportionately greater physiological effect than the matched doses of dopamine.
To review the ScopRev, see Supplement Appendix B-3.
Of note, the 2020 surviving sepsis guidelines26
suggest the use of epinephrine or norepinephrine
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compared with dopamine based on very-low-quality
evidence. The authors state that they could not make a
recommendation for a first-line vasoactive infusion for
septic shock, noting that in their practices they use epinephrine or norepinephrine.
Task Force Insights
The studies identified by the ScopRev did not evaluate
vasoactive agents other than dopamine and epinephrine
and did not include other drugs such as norepinephrine
that are commonly used to treat fluid-resistant septic
shock. The 2 RCTs were single-center studies in low- and
middle-income healthcare systems, so questions about
their generalizability to other healthcare settings arose.
The task force agreed that the adult findings could not
be extrapolated to the pediatric population because infants and children have different physiological responses
to vasoactive drugs (varying according to age even within the age range of infants and children), particularly
when compared with adult physiological responses.
The task force agreed that the current evidence does
not support the need for a SysRev and the 2010 treatment recommendations remain in effect.9,10
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
There is insufficient evidence to recommend a specific inotrope or vasopressor to improve mortality in pediatric distributive shock. The selection of an inotrope
or vasopressor to improve hemodynamics should be tailored to each patient’s physiology and adjusted to the
individual’s clinical responses.

Corticosteroids for Pediatric Septic Shock
(PLS 413: EvUp)
The PLS Task Force sought an EvUp on this topic because it was last reviewed in 2010.9,10 The evidence for
or against the use of corticosteroids in pediatric septic
shock is of very low certainty. There is limited evidence
that a specific subpopulation may benefit from the administration of corticosteroids, but these patients are not
easily identifiable at the bedside. As a result, the current
(2010) treatment recommendation continues unmodified. To review the EvUp, see Supplement Appendix C-6.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children being treated for
septic shock and circulatory failure in any setting,
during the first hours of treatment
• Intervention: Early administration of corticosteroids
• Comparator: No corticosteroid or postponed
administration
• Outcome: All
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• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was conducted to December 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
There is insufficient evidence to support or refute the
routine use of stress-dose or low-dose hydrocortisone
and/or other corticosteroids in infants and children with
septic shock. Stress-dose corticosteroids may be considered in children with septic shock unresponsive to fluids
and requiring vasoactive support.

PALS: RECOGNITION AND PREARREST
TREATMENTS FOR SHOCK
Graded Volume Resuscitation for Traumatic/
Hemorrhagic Shock (PLS 400: ScopRev)

Downloaded from http://ahajournals.org by on June 22, 2022

Rationale for Review
The PLS Task Force reevaluated this topic because the
previous review was published in 2010.9,10 This 2020
ScopRev sought to identify available evidence about the
effectiveness of graded volume resuscitation compared
with standard care for traumatic hemorrhagic shock.
To review the ScopRev, see Supplement Appendix B-3.
The term graded volume resuscitation includes restrictive volume resuscitation and permissive hypotension, with volume administered to resuscitate a hypovolemic trauma victim with relatively small volumes,
repeated to restore perfusion to a specific target.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in hemorrhagic
shock following trauma in any setting
• Intervention: Graded volume resuscitation (now
restrictive volume resuscitation)
• Comparator: Standard care
• Outcome: Any clinical outcome
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was from March 2009 to November 2019.
Summary of Evidence
Seven retrospective pediatric studies were identified.41–47 All were derived from trauma registries. Only
1 study assessed the volume of fluid given to children
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with traumatic injuries in the prehospital setting.41 Four
studies compared the total crystalloid volume given in
24 hours,42,44–46 and 1 study assessed the volume of
crystalloid given to patients needing transfusion.43 The
study that reported the critical outcome of survival to
24 hours41 found no benefit to survival associated with
graded/“limited” volume compared with standard care
for trauma resuscitation. None reported on survival at
30 days with good neurological outcome. For the critical outcome of survival to discharge, 4 studies found
no benefit associated with graded/limited volume administration compared with standard care.41,44,46,47 One
study reported lower survival to hospital discharge associated with high-volume crystalloid administration
(greater than 60 mL/kg per 24 hours) compared with
low- and moderate-volume crystalloid administration (ie, 0–40 mL/kg per 24 hours or 40–60 mL/kg per
24 hours),42 and 1 reported lower survival rates associated with higher administered crystalloid volumes (ie,
greater than 150 mL/kg per 24 hours compared with
150 mL/kg or less per 24 hours) among those receiving massive transfusions.43 Five studies reported an increased hospital or intensive care length of stay associated with higher crystalloid volume administration in
the first 24 hours.42–44,46,47 All studies were retrospective,
and they reported different interventions on differing
patient populations and differing associated outcomes.
Although it is difficult to compare results, there is a suggestion of a possible advantage of using limited volume
resuscitation. To review the ScopRev, see Supplement
Appendix B-4.
Task Force Insights
The task force discussed the term graded resuscitation
used in the 2010 CoSTR evidence evaluation; this term
was infrequently found in the trauma literature published in the past decade. The task force discussed the
definition of hypotensive resuscitation in children and
infants with trauma (because it was agreed that this is
unclear in the literature), as well as other terms used
in trauma resuscitation, such as restrictive resuscitation
and delayed versus early resuscitation.
Adult data favor restrictive volume resuscitation, and
the recommendations for this population have been to
promote damage control resuscitation. The National
Institute for Health and Care Excellence trauma guidelines48 and the American College of Surgeons Advanced
Trauma Life Support guidelines49 follow these principles
for adult practice because both suggest restrictive volume resuscitation with early use of blood components
in hemorrhagic shock.
The task force discussed the ILCOR mandate and
whether it includes the review and analysis of trauma
resuscitation topics. Because trauma remains a major
cause of death in children worldwide and there is still
a lack of evidence-based guidelines, most task force
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members agreed that this is an important issue for ILCOR to address.
RCTs or, in their absence, studies from large trauma
registries are required to address the effects of different
volume resuscitation strategies on mortality and morbidity outcomes. Optimal timing for the administration
of fluid resuscitation in pediatric trauma was not addressed in this review but will be considered for a future
SysRev.
The task force agreed that more data are needed,
but this ScopRev did not identify sufficient new evidence to prompt a new SysRev, so the 2010 treatment
recommendation (noting insufficient evidence to make
a recommendation) remains in place.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
There is insufficient evidence about the best timing
or quantity for volume resuscitation in infants and children with hemorrhagic shock following trauma.

Timing of Intubation for Shock (PLS 399:
EvUp)
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The evidence to support specific timing of intubation for infants and children in shock (ie, all types
of shock) was most recently evaluated in 2010.9,10
At that time, the PLS Task Force noted the paucity
of published evidence. This EvUp was undertaken to
identify any relevant evidence published thereafter.
Once again, insufficient evidence was found to warrant the suggestion of a pediatric SysRev. Only 5 animal studies, one 1 adult study and the 2020 Society
of Critical Care Medicine Surviving Sepsis Campaign
International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction
in Children26 were identified. The 2020 surviving
sepsis guidelines authors noted they were “unable
to make a recommendation about whether to intubate children with fluid-refractory-catecholamineresistant septic shock. However, in our practice, we
commonly intubate children [with] fluid-refractorycatecholamine-resistant septic shock without respiratory failure.”26 To review the EvUp, see Supplement
Appendix C-7.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in shock
• Intervention: Early intubation and assisted
ventilation
• Comparator: The use of these interventions only
for respiratory failure
• Outcome: Improved patient outcomes (hemodynamics, survival)
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• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to December 2019.
Treatment Recommendation
This treatment recommendation (below) is unchanged
from 2010.9,10
There is insufficient evidence to support or refute the
use of endotracheal intubation of infants and children in
shock before the onset of respiratory failure.

Prearrest Care of the Infant or Child With
Dilated Cardiomyopathy or Myocarditis
(PLS 819: EvUp)
This EvUp was performed because the most recent PLS
CoSTR on the topic of prearrest care for a child with
dilated cardiomyopathy or myocarditis was in 2015.11,12
The management of these patients has continued to
evolve since then, noting that the EvUp identified an
additional 5 studies not captured in the 2015 CoSTR.
The task force agreed to consider a request for a
SysRev to assess those studies and any others identified
pertaining to the prearrest care of an infant or child
with myocarditis. Until a new SysRev is completed and
analyzed by the PLS Task Force, the 2015 treatment
recommendation (noting insufficient evidence to make
a recommendation) remains in effect. To review the
EvUp, see Supplement Appendix C-8.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with myocarditis or
dilated cardiomyopathy and impending cardiac arrest
• Intervention: A specific approach
• Comparator: The usual management of shock or
cardiac arrest
• Outcome: Survival with favorable neurological/
functional outcome at discharge, 30 days, 60 days,
180 days, and/or 1 year; survival to hospital discharge; cardiac arrest frequency; ROSC
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was completed in September 2019.
Treatment Recommendation
This treatment recommendation (below) is unchanged
from 2015.11,12
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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The confidence in effect estimates is so low that the
panel decided that a specific recommendation was too
speculative.

Cardiogenic Shock and Inotropes (PLS
418: EvUp)
This EvUp was undertaken because the most recent
CoSTR on the topic was published in 2010,9,10 and the
task force sought to identify any studies published after
that review. The task force agreed that there is insufficient evidence identified in the EvUp to consider a request for a SysRev. As a result, the 2010 treatment recommendations9,10 remain in place. To review the EvUp,
see Supplement Appendix C-9.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children who are being
treated for cardiogenic shock in any setting, during the first hours of treatment
• Intervention: The early addition of certain vasoactive drugs
• Comparator: Postponed administration and/or a
specific vasoactive drug versus another
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to December 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
The catecholamine dose for inotropic support in
cardiogenic shock must be titrated for each individual
because there is wide variability in the clinical response
to vasoactive drugs. It is reasonable to use epinephrine, levosimendan, dopamine, or dobutamine for inotropic support in infants and children with cardiogenic
shock. Milrinone may be beneficial for the prevention
and treatment of low cardiac output following cardiac
surgery. There are insufficient data to support or refute the use of norepinephrine in pediatric cardiogenic
shock.

PALS: MANAGEMENT OF
DETERIORATION WITH PULMONARY
HYPERTENSION
This section includes 3 topics about the management
and prevention of critical pulmonary hypertension

Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894

Pediatric Life Support: 2020 CoSTR

crises in the infant or child. All were evaluated by EvUps
to identify the availability of evidence published after
the most recent review of the management of infants
and children with pulmonary hypertension (appeared in
the literature in 2010).9,10

Prevention and Management of
Postoperative Pulmonary Hypertensive
Crises in Infants and Children (PLS 391:
EvUp)
Although the general topic of pulmonary hypertension
was reviewed in the 2010 CoSTR,9,10 the focus was on
treatment of cardiac arrest in patients with pulmonary
hypertension. This EvUp was performed to identify any
evidence about the postoperative care of infants and
children with pulmonary hypertension at high risk of
pulmonary hypertensive crisis. The EvUp identified several RCTs. In addition, the PLS Task Force is aware of 3
scientific publications—2 from the American Heart Association (AHA)50,51 and 1 from the European Pediatric
Pulmonary Vascular Disease Network51a—each group
having completed a SysRev in 2015. The task force
agreed that the EvUp identified sufficient published evidence to indicate the need to consider a SysRev. Until
such time as a new SysRev is completed and analyzed
by the PLS Task Force, the 2010 treatment recommendation remains in effect for treatment of children with
pulmonary hypertension and cardiac arrest. To review
the EvUp, see Supplement Appendix C-10.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with pulmonary
hypertension at high risk of postoperative pulmonary hypertensive crises
• Intervention: Postoperative care such as careful
respiratory management and monitoring to avoid
hypoxia and acidosis
• Comparator: Standard postoperative care
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to November 2019.
Treatment Recommendations
This treatment recommendation for the care of children with pulmonary hypertension and cardiac arrest
(below) is unchanged from 2010.9,10
Rescuers should provide conventional PALS, including oxygenation and ventilation, for cardiac arrest
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associated with pulmonary hypertension. It may be
beneficial to attempt to correct hypercarbia. If the administration of medications (IV or inhaled) to decrease
pulmonary artery pressure has been interrupted, it may
be advisable to reinstitute it.
Inhaled nitric oxide or aerosolized prostacyclin or analogues to reduce pulmonary vascular resistance should
be considered. If these are unavailable, an IV bolus of
prostacyclin may be considered.
Note: A SysRev will be needed to generate treatment
recommendations for postoperative care of children
with pulmonary hypertension at risk for pulmonary hypertensive crisis.

Opioids, Sedatives, and Neuromuscular
Blocking Drugs for Pulmonary
Hypertension (PLS New: EvUp)
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Although the general topic of pulmonary hypertension was reviewed in the 2010 CoSTR,9,10 the focus
was on treatment during cardiac arrest; there were
no specific PICOST questions and no treatment recommendations about the use of opioids, sedatives,
and neuromuscular blocking drugs for an infant or
a child with pulmonary hypertension who is not in
cardiac arrest. The PLS Task Force is aware of 3 scientific publications—2 from the AHA50,51 and 1 from
the European Pediatric Pulmonary Vascular Disease
Network51a—each group having completed a SysRev
in 2015. To review the EvUp, see Supplement Appendix C-11. The PLS Task Force agreed to consider the
need for a SysRev to evaluate the available evidence
and see if treatment recommendations were required
after review of the literature.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children at high risk of pulmonary hypertensive crises
• Intervention: Provision of adequate opiates, sedatives, and neuromuscular blocking drugs
• Comparator: Standard care without opiates
• Outcome: All, especially pulmonary hypertensive
crises
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to November 2019.
Treatment Recommendations
There are no previous treatment recommendations.
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Therapy With Inhaled Nitric Oxide
or Prostaglandin I2 for Pulmonary
Hypertensive Crisis and Right Heart
Failure (PLS New: EvUp)
Although the general topic of pulmonary hypertension
was reviewed in the 2010 CoSTR,9,10 the focus was
on the treatment of cardiac arrest; this 2020 EvUp focused on the evidence supporting inhaled nitric oxide
or prostaglandin I2 to manage pulmonary hypertensive
crises and right heart failure in infants and children
with or without cardiac arrest. This EvUp identified 3
scientific publications—2 from the AHA50,51 and 1 from
the European Pediatric Pulmonary Vascular Disease
Network51a—each group having completed a SysRev
in 2015. In addition, a previous EvUp (see Supplement
Appendix C-12) identified a SysRev52 that reported the
results of an RCT on inhaled nitric oxide for the postoperative treatment of pulmonary hypertension.53
The EvUp and the PLS Task Force member group
identified sufficient published data about the use
of inhaled nitric oxide and prostaglandin I2 to consider recommending a SysRev to evaluate the available evidence and, if required, make new treatment
recommendations. Until a new SysRev is completed
and analyzed, the 2010 treatment recommendations
remain in effect for the general management of pulmonary hypertension and not specifically to address
this PICOST because that will require further analysis
of the literature.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children at high risk of pulmonary hypertensive crises
• Intervention: Provision of pulmonary vasodilators
such as inhaled nitric oxide or prostaglandin I2
• Comparator: Standard therapy with no provision
of therapy such as inhaled nitric oxide or prostaglandin I2
• Outcome: Alter the outcome of pulmonary hypertensive crises or acute right heart failure
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to November 2019.
Treatment Recommendations
The broad treatment recommendations published in
2010, regarding inhaled nitric oxide, remain in effect.9,10
Rescuers should provide conventional PALS, including
oxygenation and ventilation for cardiac arrests associated with pulmonary hypertension. It may be beneficial
to attempt to correct hypercarbia. If the administration
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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of medications (IV or inhaled) to decrease pulmonary
artery pressure has been interrupted, it may be advisable to reinstitute it.
Inhaled nitrous oxide or aerosolized prostacyclin
or analogue to reduce pulmonary vascular resistance
should be considered. If unavailable, an IV bolus of
prostacyclin may be considered.

PALS: RECOGNITION AND TREATMENT
OF NONARREST ARRHYTHMIAS
Drugs for Supraventricular Tachycardia
(PLS 379: EvUp)
This topic was last reviewed in 2010.9,10 This EvUp was
to identify any evidence about the management of supraventricular tachycardia in infants and children published after 2010. The EvUp identified 6 studies; all were
retrospective and observational, and none compared
adenosine with other IV drugs for the management and
resolution of supraventricular tachycardia. The PLS Task
Force concluded that there was insufficient evidence to
suggest the need for a SysRev and no need to consider
a change in the previous (2010) treatment recommendations.9,10 To review the EvUp, see Supplement Appendix C-13.
Downloaded from http://ahajournals.org by on June 22, 2022

Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with supraventricular tachycardia with a pulse
• Intervention: Use of any drug or combination of
drugs
• Comparator: Adenosine
• Outcome: Termination of abnormal rhythm,
survival
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract from ILCOR 2010
guidance. The search was performed in November
2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
For infants and children with supraventricular tachycardia with a palpable pulse, adenosine should be considered the preferred medication. Verapamil may be
considered an alternative therapy in older children, but
it should not be routinely used in infants. Procainamide
or amiodarone given by a slow IV infusion with careful hemodynamic monitoring may be considered for
refractory supraventricular tachycardia.
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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Note: The 2020 PLS Task Force wishes to add the
caveat that expert consultation is encouraged before
the use of procainamide or amiodarone.

Treatment for Unstable
Ventricular Tachycardia (PLS 409: EvUp)
The management of unstable VT was last reviewed
in 2010.9,10 This 2020 EvUp was to determine if there
was sufficient evidence to consider a SysRev. The task
force concluded that there was insufficient published
evidence of the management of unstable tachycardia
to recommend the consideration of a SysRev, so the
2010 treatment recommendations remain in effect.9,10
To review the EvUp, see Supplement Appendix C-14.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with unstable ventricular tachycardia (prehospital and in-hospital)
• Intervention: Any drug, combination of drugs, or
intervention (eg, cardioversion)
• Comparator: No drugs or intervention
• Outcome: Termination of rhythm, survival
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The search was
finished in November 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
It is reasonable to use synchronized electric cardioversion as the preferred first therapy for pediatric
VT with hypotension or evidence of poor perfusion.
If drug therapy is used to treat unstable VT, amiodarone may be a reasonable choice, with careful
hemodynamic monitoring performed during its slow
delivery.

CPR for Heart Rate of Less Than 60/min
(PLS 1535: EvUp)
PLS council guidelines54,55 recommend that PLS providers begin chest compressions if an infant or child
has a heart rate under 60 beats per minute with signs
of poor perfusion despite support of the airway, adequate oxygenation, and ventilation; this recommendation represents expert consensus provided by council
guidelines rather than by an ILCOR evidence review.
No previous search strategy was identified for this topic. As a result, a new search strategy was developed.
The EvUp identified 2 nonrandomized studies that
October 20, 2020
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documented improved outcomes associated with CPR
for bradycardia with pulses and poor perfusion when
compared with outcomes associated with pulseless
electric activity or asystole cardiac arrest without preceding chest compressions.56,57 Lower survival was associated with longer time intervals between the start
of CPR for bradycardia with pulse and poor perfusion,
and the loss of the pulse.56
Although the evidence base is limited, the task force
agreed that the importance of the question when to
initiate CPR for bradycardia suggests the need for consideration of a SysRev. To review the EvUp, see Supplement Appendix C-15.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children who are in cardiac
arrest
• Intervention: Starting CPR if they have a heart rate
of less than 60/min with signs of shock and with a
palpable pulse
• Comparator: Starting CPR for patients with a heart
rate of less than 60/min and no palpable pulse
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion; unpublished studies (eg, conference
abstracts, trial protocols) excluded
• Time frame: All years since 2010 and all languages
were included if there was an English abstract until
December 2019.
Treatment Recommendations
There is no ILCOR PLS treatment recommendation at
this time.

Drugs for the Treatment of Bradycardia:
Atropine Versus No Atropine and
Atropine Versus Epinephrine (PLS New:
EvUps)
The PLS Task Force reviewed this topic in 2010. Two
EvUps were performed to determine if any studies were
published after 2010 about atropine compared with
epinephrine (see Supplement Appendix C-16) and atropine compared with no atropine (see Supplement Appendix C-17) for the treatment of bradycardia in infants
or children. The EvUps identified no studies published
after 2010. After completion of the reviews, however,
the task force identified 1 nonrandomized (in-hospital
registry) study about epinephrine for children receiving
CPR for bradycardia and poor perfusion.58 The PLS Task
Force agreed that there remains insufficient evidence
for consideration of a SysRev; as a result, the 2010
treatment recommendation remains in effect.9,10
9,10
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with bradycardia
for any reason
• Intervention: Use of atropine at a specific dose
• Comparator: Not using atropine, using another
drug, or using it [atropine] at a different dose
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was conducted in November 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
Epinephrine may be administered to infants and
children with bradycardia and poor perfusion that is
unresponsive to ventilation and oxygenation. It is reasonable to administer atropine for bradycardia caused
by increased vagal tone or anti-cholinergic drug toxicity. There is insufficient evidence to support or refute
the routine use of atropine for pediatric cardiac arrest.

Emergency Transcutaneous Pacing for
Bradycardia (PLS New: EvUp)
This topic was last addressed by the Pediatric Task Force
in 2000,59 when an international consensus on science
and international guidelines were published. As a result, the PLS Task Force requested an EvUp to determine
if there was relevant evidence to suggest the need to
consider a SysRev. After review of the EvUp (see Supplement Appendix C-18), the task force agreed that there
is insufficient evidence to suggest the need for a SysRev. As a result, the 2000 treatment recommendation
remains in effect.59
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• There was no previous PICOST for this question.
See Supplement Appendix C-18 for details of the
search strategy.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2000.59
In selected cases of bradycardia caused by complete
heart block or abnormal function of the sinus node,
emergency transthoracic pacing may be lifesaving. Pacing is not helpful in children with bradycardia secondary
to a postarrest hypoxic/ischemic myocardial insult or respiratory failure. Pacing was not shown to be effective
in the treatment of asystole in children.
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894

Maconochie et al

Pediatric Life Support: 2020 CoSTR

Channelopathies (PLS 417: EvUp)

PALS: MANUAL DEFIBRILLATION

The topic of channelopathies was last addressed in the
PLS 2010 CoSTR.9,10 That review as well as this 2020
EvUp considered a channelopathy after either sudden,
unexplained death in children or after an attempted resuscitation following sudden unexplained cardiac arrest
in a previously healthy child or young adult.
One issue identified in both the 2010 and this 2020
evidence evaluation is that there is a role for selective
screening for inheritable heart disease and channelopathy where indicated but that expert advice should be
sought in this regard. To review the EvUp see Supplement Appendix C-19. The 2010 treatment recommendation remains in effect.9,10 For clarity, the task force
modified the first sentence to begin with “Following
attempted resuscitation for” before “sudden cardiac
arrest” to make clear that the screening is performed
after resuscitation efforts, not during them.

This section includes several topics on the subject of
pediatric manual defibrillation, including pad size and
type and pad or paddle placement during defibrillation,
the use of stacked shocks, and the evidence about defibrillation energy dose in infants and children.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
The following PICOST elements were used in the 2010
review.9,10
• Population: Infants and children undergoing resuscitation from cardiac arrest
• Intervention: Consideration of a channelopathy as
the etiology of the cardiac arrest
• Comparator: Standard management
• Outcome: ROSC, survival to discharge, survival
with favorable neurological outcome
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract in ILCOR. The
search was performed in November 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
After attempted resuscitation for sudden unexplained
cardiac arrest, providers should obtain a thorough history
(including syncopal episodes, seizures, unexplained accidents/ or drownings, or sudden death) and review any
available previous electrocardiograms. All infants, children, and young adults with sudden, unexpected death
should, if possible, have an unrestricted complete autopsy, preferably performed by pathologists with training
and expertise in cardiovascular pathology. Consideration
should be given to the reservation and genetic analysis
of tissue from the index patient to determine the presence or absence of a channelopathy. It is recommended
that families of patients who child’s cause of death is not
found on autopsy be referred to a healthcare provider
or center with expertise in cardiac rhythm disturbances.
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Pad Size, Type, and Placement for
Pediatric Defibrillation (PLS 378 and
PLS 043: EvUp)
The topics of pad size and placement and adhesive pads
compared with paddles were last reviewed in 2010.9,10
In the decade after that review, the technological advances were rapid, hence an EvUp was performed to
identify any relevant evidence published after 2010.
The PLS Task Force agreed to combine these topics into
a single EvUp because they expected to identify relatively little evidence. (To review the EvUp, see Supplement Appendix C-20). The task force agreed that the
EvUp did not identify sufficient evidence to suggest the
need to consider a SysRev, so the 2010 treatment recommendations for both topics remain in effect.9,10
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in cardiac arrest
in any setting
• Intervention: Specific use of self-adhesive pads or
any specific paddle or pad size, orientation, and
position
• Comparator: Use of paddles or any other paddle
or pad size, orientation, and position
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was from 2010 to December 2019.
Treatment Recommendations
These treatment recommendations (below) are unchanged from 2010.9,10
There is insufficient evidence to alter the current recommendations to use the largest size paddles that fit
an infant’s or child’s chest without touching each other
or to recommend one paddle or pad position or type
over another.
Either self-adhesive defibrillation pads or paddles
may be used in infants and children in cardiac arrest.
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Energy Doses for Defibrillation (PLS 405:
ScopRev)
Rationale for Review
In the 2015 CoSTR,11,12 the PLS Task Force recommended
an initial dose of 2 to 4 J/kg to treat shockable rhythms
of cardiac arrest. There are differences in the first shock
dose recommended by ILCOR member councils, however, with the European Resuscitation Council recommending 4J/kg for the first and all subsequent shocks55
and the AHA recommending an initial dose of 2 to 4 J/kg
(but for ease of teaching, a dose of 2 J/kg is used in algorithms and training materials). For refractory VF, the AHA
guidelines recommend increasing the defibrillation dose
to 4 J/kg, suggesting that subsequent energy doses should
be at least 4 J/kg and noting that higher levels may be
considered, not to exceed 10 J/kg.60 The task force undertook this review to determine if sufficient evidence exists
to recommend consideration of a SysRev that may result
in greater consistency in doses recommended for pediatric
manual defibrillation. See Supplement Appendix B-5.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children who are in VF or
pVT in any setting
• Intervention: Specific energy dose or regimen of
energy doses for the initial or subsequent defibrillation attempt(s)
• Comparator: 2 to 4 J/kg
• Outcome: Harm to the patient, ROSC, hospital
discharge, long-term survival, survival with good
neurological outcome
Summary of Evidence
The review identified a single 2019 SysRev61 of pediatric
human and animal studies that met the search criteria. The SysRev identified no studies linking the initial
or cumulative energy delivered to survival to hospital
discharge and no link between long-term survival or
survival with good neurological outcome. Meta-analysis
could not be performed because the component population groups were extremely heterogeneous.
Task Force Insights
Shockable rhythms are less common in infants and children with OHCA (less than 10%62,63) compared with
in-hospital cardiac arrest (IHCA) (5% to 24%64,65) and
less common in pediatric than in adult OHCA66 and in
IHCA.64 The task force acknowledged that the lower
frequency of occurrence does affect the sample size for
studies to demonstrate statistically significant improvement in survival associated with different defibrillation
energy doses.
It may be difficult to determine accurately the
precise weight of children with OHCA in the prehospital arena (as may be the case in the emergency
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department setting for such patients), hence the calculation of defibrillation doses administered in J/kg
could be imprecise. In addition, the interval from cardiac arrest to the delivery of first shock and the quality
of CPR could each influence the outcomes for VF or
pVT survival after shock delivery.
None of the studies identified in the single SysRev61
found a significant association between the initial defibrillation energy dose and the rate of sustained ROSC
or survival. The task force agreed to prioritize this topic
for consideration of a SysRev; until it is completed and
reviewed, the 2015 treatment recommendation remains in effect.11,12
Note: In June 2020, task force members received a
PubMed automated alert about the publication of a
new study of energy doses for pediatric defibrillation.
The task force chair (IM) repeated the original search
and verified that the study identified67 was the only
study meeting the search criteria published since the
November 2019 search on the topic. The new in-hospital registry study identified 422 infants and children
18 years of age or younger with cardiac arrest and initial VF/pVT. First shock energy doses other than 1.7 to
2.5 J/kg were associated with lower survival to hospital
discharge among the 301 patients 12 years of age or
younger with initial VF/pVT, and first shock doses more
than 2.5 J/kg were associated with lower survival rates
in all patients 18 years of age or younger with initial
VF.67 There was insufficient time for the task force to
analyze the study or its conclusions before submission
of this PLS CoSTR, but the task force did want to acknowledge this additional new publication.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2015.11,12
We suggest the routine use of an initial dose of
2 to 4 J/kg of monophasic or biphasic defibrillation
waveforms for infants or children in VF or pVT cardiac arrest (weak recommendation, very-low-quality
evidence). There is insufficient evidence on which to
base a recommendation for second and subsequent
defibrillation doses.

Single or Stacked Shocks for Pediatric
Defibrillation (PLS 389: EvUp)
The evaluation of the evidence in support of single
compared with stacked shocks for pediatric defibrillation was most recently addressed in 2010.9,10 The task
force undertook this EvUp to identify any new evidence
published after 2010. The task force agreed that there
was no new evidence to suggest the need to consider
a request for a SysRev or to change the 2010 treatment
recommendation. To review the EvUp, see Supplement
Appendix C-21.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in VF or pVT in
any setting
• Intervention: More than 1 shock for the initial or
subsequent defibrillation attempt(s)
• Comparator: A single shock
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated in December 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
A single-shock strategy followed by immediate
CPR (beginning with chest compressions) is recommended for children with out-of-hospital or in-hospital VF or pVT.

PALS: AIRWAYS, OXYGENATION, AND
VENTILATION
Downloaded from http://ahajournals.org by on June 22, 2022

Central to the management of the critically ill or injured
child is to ensure that the airway is patent and that ventilation and oxygenation are effective.
In this section, the evidence evaluations for the following airway and oxygenation and ventilation topics are summarized: ventilation rate when a perfusing
rhythm is present, oxygen concentration during cardiac arrest, ventilation during CPR with bag and mask
compared with an advanced airway, use of cuffed or
uncuffed tracheal tubes, minute ventilation during cardiac arrest, use of cricoid pressure during intubation,
use of devices to verify advanced airway placement,
and ventilation rate with an advanced airway during
cardiac arrest.

Ventilation Rate When a Perfusing
Rhythm Is Present (PLS 3103A and PLS
382: EvUp)
This EvUp was undertaken to determine if there was
published evidence to support the recommendation to
deliver 1 breath every 3 seconds or any other specific
ventilation rate for infants and children who require
bag-mask ventilation but have a pulse and perfusing
rhythm. The 2000 CoSTR on pediatric basic life support noted, “the goal of ventilation with a bag and
mask should be to approximate normal ventilation
and achieve physiological oxygen and carbon dioxide
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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concentration while minimizing risk of iatrogenic injury.”68 The recommendation was based on expert consensus rather than a formal review of the evidence on
the subject. To review the EvUp, see Supplement Appendix C-22.
The PLS Task Force has not made any previous recommendations for specific ventilation rate for the infant or child with respiratory arrest and a perfusing
rhythm. Such recommendations have been included
in council guidelines rather than in the ILCOR CoSTRs.
The search conducted in December 2019 for this EvUp
did not reveal any relevant evidence, and the task force
concluded that there was no need to consider a recommendation for a SysRev.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with a perfusing
rhythm but absent or inadequate respiratory effort
• Intervention: Giving 1 breath every 3 to 5 seconds
(12–20 breaths/min)
• Comparator: Alternative ventilation rates
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated in February 2019.
Treatment Recommendations
No treatment recommendations will be made until a
future SysRev identifies sufficient evidence to make a
recommendation.

Oxygen Concentration During Cardiac
Arrest (PLS 396: ScopRev)
Rationale for Review
The published evidence supporting a specific inspired
oxygen concentration to use during attempted resuscitation of infants and children was last reviewed in
2010.9,10 To review the ScopRev, see Supplement Appendix B-6.
The evidence supporting titration of oxygen after
ROSC is addressed in a separate review; see Oxygen
and Carbon Dioxide Targets in Pediatric Patients With
Return of Spontaneous Circulation After Cardiac Arrest.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants (age 28 days to 12 months)
and children in cardiac arrest in any setting
• Intervention: Fraction of inspired oxygen (Fio2)
titrated to oxygenation during cardiac arrest
• Comparator: Use of 100% oxygen (Fio2 1.00)
October 20, 2020
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• Outcome: Any
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to October 2019.
Summary of Evidence
The ScopRev identified no human studies in infants (beyond the neonatal period) and children about oxygen
concentration or its titration during cardiopulmonary
resuscitation. The ScopRev identified 2 SysRevs69,70 and
a 2019 ILCOR CoSTR summary statement71,72 about
initial resuscitation of newborns, although these were
not relevant to this 2020 ScopRev. This is because they
pertained to the resuscitation of newborns in the first
minutes of life (ie, during the transition from placental
to pulmonary oxygenation).
The ScopRev identified 2 studies in immature animal
models,73,74 a SysRev with meta-analysis of neonatal animal models,75–77 and 2 mature animal studies.78,79 From
this body of work there appeared to be no difference in
ROSC rates but greater evidence of metabolic derangement associated with the administration of 100% oxygen during resuscitation of the animals.
Downloaded from http://ahajournals.org by on June 22, 2022

Task Force Insights
There were no human studies in infants or children
that addressed the topic, and the indirectness of results
from animal models were considered insufficient to alter the existing 20109,10 treatment recommendation.
Also see Oxygen and Carbon Dioxide Targets in Pediatric Patients With Return of Spontaneous Circulation
After Cardiac Arrest below.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010. Note that the task force deleted a second
recommendation that was included in the 2010 treatment recommendations regarding Fio2 after ROSC because it is addressed in a separate 2020 treatment recommendation.9,10
There is insufficient information to recommend a
specific inspired oxygen concentration for ventilation
during attempted resuscitation after cardiac arrest in
infants and children.

Ventilation During CPR With Bag and
Mask Compared With an Advanced
Airway (2019 CoSTR)
A 2019 SysRev80 and an ILCOR Pediatric CoSTR
statement were published as part of the 2019
CoSTR summary.71,72 The publications addressed
advanced airway interventions for pediatric cardiac
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arrest, comparing bag-mask ventilation with ventilation through an advanced airway. Refer to those
publications for details of the evidence summary
and task force considerations.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in any setting
(in-hospital or out-of-hospital) who have received
chest compressions or a shock and are receiving
CPR
• Intervention: Placement of an advanced airway
device
• Comparator: Primary—bag-mask ventilation alone
or with non–advanced airway interventions; secondary—another advanced airway device
• Outcome: Any clinical outcome
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to January 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2019, with the minor addition of “or insertion of”
before “a supraglottic airway.”71,72
We suggest the use of bag-mask ventilation rather
than tracheal intubation or insertion of a supraglottic
airway in the management of children with cardiac arrest in the out-of-hospital setting (weak recommendation, very-low–certainty evidence).
There is insufficient evidence to support any recommendation about the use of tracheal intubation or
insertion of a supraglottic airway in the management
of children with cardiac arrest in the in-hospital setting.

Use of Cuffed or Uncuffed Tracheal Tubes
(PLS 412: EvUp)
The PLS Task Force last reviewed the evidence
comparing cuffed with uncuffed tracheal tubes in
2010.9,10 This 2020 EvUp was to identify any evidence on the topic published after 2010. The EvUp
identified 3 SysRevs, 2 RCTs, and 3 observational
studies published since the previous evidence review.
To review the EvUp, see Supplement Appendix C-23.
The task force agreed that the evidence identified by
the 2020 EvUp supports the consideration of a SysRev about the use of cuffed versus uncuffed tubes
in cardiopulmonary resuscitation to ascertain if the
treatment recommendation requires modification.
Until the completion and analysis of a new SysRev,
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the 2010 treatment recommendation remains in effect.9,10
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with respiratory
failure who undergo endotracheal intubation in
any setting
• Intervention: Use of cuffed tracheal tubes
• Comparator: Use of uncuffed tracheal tubes
• Outcome: Any
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to December 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
Both cuffed and uncuffed tracheal tubes are acceptable for infants and children undergoing emergency
intubation. If tracheal tubes are used, avoid excessive
cuff pressures.

Downloaded from http://ahajournals.org by on June 22, 2022

Atropine for Emergency Intubation (PLS
821: EvUp)
The PLS Task Force reviewed the evidence about the
routine use of atropine as a premedication before
emergency intubation in 2015.11,12 An EvUp was undertaken but found insufficient literature for consideration of a SysRev. To review the EvUp, see Supplement Appendix C-24. The 2015 CoSTR remains in
effect.11,12
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children requiring emergency tracheal intubation
• Intervention: Use of atropine as a premedication
before intubation
• Comparator: No use of atropine
• Outcome: Survival with favorable neurological
outcome at 180 days, survival to hospital discharge, survival with favorable neurological outcome at 30 days follow-up, survival with favorable
neurological outcome at discharge, likelihood of
cardiac arrest, likelihood of shock, incidence of
arrhythmias
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to September 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2015.11,12
The confidence in effect estimates is so low that
the panel decided that a recommendation was too
speculative.

Cricoid Pressure During Intubation (PLS
376: EvUp)
The PLS Task Force last reviewed the evidence about
the use of cricoid pressure during tracheal intubation
in 2010.9,10
The EvUp identified 2 observational studies suggesting an association between external laryngeal manipulation, such as cricoid pressure, and increased difficulty
during tracheal intubation of children in the emergency
setting. To review the EvUp, see Supplement Appendix
C-25. The PLS Task Force concluded that they should
consider the need for a comprehensive SysRev to determine if the 2020 treatment recommendation should
be amended. Until a new SysRev is completed and analyzed by the PLS Task Force, the 2010 treatment recommendation remains in effect.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children treated for acute
illness or injury in any setting, during first hour of
treatment
• Intervention: Use of cricoid pressure or laryngeal
manipulation during endotracheal intubation
• Comparator: Any other type of or no laryngeal
manipulation
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to December 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
If cricoid pressure is used during emergency intubation in infants and children, it should be discontinued
if it impedes ventilation or interferes with the speed or
ease of intubation.
October 20, 2020

S161

Maconochie et al

Use of Devices to Verify Advanced
Airway Placement (PLS 385: EvUp)
This 2020 EvUp was undertaken to determine if there
was new evidence to support the use of devices to confirm advanced airway placement published after the
most recent review of the topic in 2005.81,81a The EvUp
identified 1 SysRev,82 relevant output from national surveys,83 and 2 RCTs.84,85 Although these studies chiefly
involved adults or preterm infants rather than infants
beyond 28 days of age or children, the PLS Task Force
agreed that there is sufficient new evidence to suggest the need to consider a SysRev. Until a new SysRev
is completed and analyzed by the PLS Task Force, the
2005 treatment recommendation remains in effect. To
review the EvUp, see Supplement Appendix C-26.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children who are in respiratory failure who undergo endotracheal intubation in any setting
• Intervention: The use of devices (eg, CO2 detection device, CO2 analyzer, or esophageal detector
device)
• Comparator: Not using such a device
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to November 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2005.81 The task force agreed to remove the
weight minimum of 20 Kg or greater for capnography.
In addition, the task force noted that continuous monitoring of waveform capnography has now become routine in many settings.
Confirmation of tracheal tube position using exhaled
CO2 detection (colorimetric detector or capnography)
should be used for intubated infants and children with
a perfusing cardiac rhythm in all settings (eg, out-ofhospital, emergency department, intensive care unit,
inpatient, operating room). In infants and children with
a perfusing rhythm, it may be beneficial to monitor
continuous capnography or frequent intermittent detection of exhaled CO2 during out-of-hospital and intrahospital or interhospital transport.
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Ventilation Rate With Advanced Airway
During Cardiac Arrest (PLS 3103A and PLS
382: EvUp)
The 2010 CoSTR was the most recent review of the
evidence about optimal minute ventilation (product of
tidal volume and respiratory rate/min) after the placement of an advanced airway during CPR in infants or
children. The minute ventilation recommended in the
2010 CoSTR was based on expert consensus.9,10
This 2020 EvUp was to identify any evidence published after 2010 that might indicate the need for a
new SysRev and for possible modification of the current treatment recommendations. This EvUp was prioritized for inclusion in this 2020 CoSTR because the
task force identified the differences in recommended
or proposed minute ventilation and respiratory rates
across resuscitation councils and sought to identify
any evidence that could assist in the development of
a consistent recommended ventilation rate.
The EvUp identified a small single-center observational paper that reported an association of ventilation rates during cardiac arrest higher than 12 to
20/min with improved outcomes. 86 Ongoing studies
are anticipated to conclude later in 2020 that may
provide further data. As a result, the PLS Task Force
will await the publication of more evidence to consider the need for a SysRev and possible revision
of the treatment recommendation. To review the
EvUp, see Supplement Appendix C-27.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with cardiac arrest
and an advanced airway
• Intervention: The use of a higher ventilation rate
• Comparator: The current recommendation of 8 to
10 breaths/min
• Outcome: ROSC, survival to discharge, survival
with favorable neurological status
Treatment Recommendations
The treatment recommendations (below) are unchanged from 2010 except for a minor edit to clarify types of arrest as asphyxial or arrhythmic (rather
than VF) in origin. 9,10
After placement of a secure airway, avoid hyperventilation of infants and children during resuscitation from
cardiac arrest, whether asphyxial or arrhythmic in origin.
A reduction in minute ventilation to less than baseline for age is reasonable to provide sufficient ventilation to maintain adequate ventilation-to-perfusion ratio
during CPR while avoiding the harmful effects of hyperventilation.
There are insufficient data to identify the optimal
tidal volume or respiratory rate.
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PALS: CIRCULATORY SUPPORT DURING
CPR
Extracorporeal CPR for In-Hospital
Cardiac Arrest (2019 CoSTR)
A SysRev about extracorporeal CPR (ECPR) for pediatric
IHCA was performed in 201887 and an ILCOR Pediatric
CoSTR was published as part of the 2019 CoSTR summary.71,72 The summary of the consensus on science can
be found in that 2019 CoSTR. Refer to those publications for details of the evidence summary and task force
considerations.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Adults (age 18 years or older) and
children (age younger than 18 years) with cardiac
arrest in any setting (out-of-hospital or in-hospital)
• Intervention: Extracorporeal CPR (ECPR) including
extracorporeal membrane oxygenator therapy or
cardiopulmonary bypass during cardiac arrest
• Comparator: Manual or mechanical CPR
• Outcome: Clinical outcomes, including short-term
survival and neurological outcomes (eg, hospital
discharge, 28 days, 30 days, and 1 month) and
long-term survival and neurological outcomes (eg,
at 3 months, 6 months, and 1 year)
• Study design: RCTs and nonrandomized studies (nonRCTs, interrupted time series, controlled before-andafter studies, cohort studies) eligible for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to January 2019.
Treatment Recommendations
These treatment recommendations (below) are unchanged from 2019.71,72
We suggest that ECPR may be considered as an intervention for selected infants and children (eg, pediatric cardiac populations) with IHCA refractory to conventional CPR in settings where resuscitation systems allow
ECPR to be well performed and implemented (weak
recommendation, very low-quality evidence).
There is insufficient evidence in pediatric OHCA to formulate a treatment recommendation for the use of ECPR.

PALS: PHYSIOLOGICAL MONITORING
DURING ARREST TO GUIDE
THERAPY AND/OR INTRA-ARREST
PROGNOSTICATION
Physiological monitoring and feedback during CPR can
facilitate the adjustment of CPR delivery during resuscitation and, as a result, may improve the quality of resuscitation and even resuscitation outcomes. Such monitoring

Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894

Pediatric Life Support: 2020 CoSTR

may also allow for “individualized CPR” tailored to the
patients’ needs and their responses to resuscitation interventions. This section highlights the reviews about the
use of invasive blood pressure monitoring, bedside ultrasound, near-infrared spectroscopy, and end-tidal carbon
dioxide (ETCO2) to assist with the optimal delivery of CPR.

Invasive Blood Pressure Monitoring
During CPR (PLS 826: ScopRev)
Rationale for Review
Maintenance of adequate arterial systolic (compression) and diastolic (relaxation) or mean pressure during
CPR is crucial to maintain coronary and cerebral perfusion. Maintaining a sufficient minimum threshold blood
pressure should be associated with improved clinical
outcomes. It is unknown if CPR directed to meet individualized rather than uniform standard blood pressure
targets will improve outcomes from cardiac arrest. This
topic was most recently reviewed in 2015,11,12 and the
2020 ScopRev was performed to identify any evidence
on this topic published after 2015.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children undergoing CPR
• Intervention: Use of invasive hemodynamic monitoring to titrate to a specific systolic and diastolic
blood pressure
• Comparator: No use of invasive monitoring to a
specific systolic and diastolic blood pressure
• Outcome: Change in survival to 180 days with
good neurological outcome, survival to 60 days
with good neurological outcome, survival to hospital discharge with good neurological outcome,
the likelihood of survival to discharge or ROSC
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to November 2019.
Summary of Evidence
There was no association between blood pressures
measured during CPR and neurological outcomes in
an observational study of survivors of pediatric critical
care (including cardiac critical care).88 In an observational study of a highly selected pediatric critical care
population with arterial pressure monitoring in place
when cardiac arrest developed, there was a significant
association between the mean diastolic blood pressure
of 25 mm Hg or greater in infants and 30 mm Hg or
greater in children within the first 10 minutes postarrest
and their survival as well as with survival with favorable
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neurological function.89 To review the ScopRev, see
Supplement Appendix B-7.
Task Force Insights
The information identified in this ScopRev applies only
to pediatric patients with intra-arterial access along with
continuous monitoring of blood pressure at the time
they develop cardiac arrest. The work by Berg and colleagues89 identified an association between the mean
diastolic blood pressure associated with neurologically
intact survival and the blood pressure thresholds below
which no child survived. The evidence was too limited, however, to consider the diastolic blood pressure
threshold by itself sufficient to identify CPR futility.
The PLS Task Force considered that, for children with
IHCA and an arterial line already in place, hemodynamic-directed CPR might be considered. The task force
agreed, however, that more evidence is required and
that there is insufficient evidence currently available to
consider a request for a SysRev. The 2015 treatment
recommendation remains in effect.11,12
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2015.11,12
The confidence in effect estimates is so low that
the panel decided that a recommendation was too
speculative.
Downloaded from http://ahajournals.org by on June 22, 2022

Use of Near-Infrared Spectroscopy During
Cardiac Arrest (PLS New: ScopRev)
Rationale for Review
NIRS is a noninvasive mode of estimating regional cerebral and renal/mesenteric oxygen saturation (rSco2)
and can detect these signals in no blood flow situations as in cardiopulmonary arrest. Cerebral NIRS values can reflect cerebral physiological changes (ie,
intracranial tissue oxygenation that can be affected
by arterial blood flow, tissue perfusion, and venous
drainage) during cardiac arrest, during changes in intracranial pressure, during arrest resolution, and after ROSC. NIRS uses adhesive sensors placed on the
forehead (to evaluate regional cerebral oxygen saturation of hemoglobin rSco2 and over the abdomen.
Each sensor contains a light source and 2 fiberoptic
bundles that can detect the light absorption and reflection at different tissue depths.
This ScopRev addresses the use of NIRS as an intraarrest variable that may assist in tailoring CPR technique
to improve blood flow and oxygen delivery. The PLS
Task Force has not previously considered use of NIRS
in this manner, hence there are no current treatment
recommendations. To review the ScopRev, see Supplement Appendix B-8.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in any setting (inhospital or out-of-hospital) with cardiac arrest
• Intervention: The presence of variables—images,
cut-off values, or trends—during CPR (intra-arrest)
that can provide physiological feedback to guide
resuscitation efforts, namely NIRS and cerebral
oxygen saturation monitoring
• Comparator: The absence of such factors—
images, cut-off values, or trends
• Outcome: Any clinical outcome
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to October 2019.
Summary of Evidence
The ScopRev identified no pediatric RCTs but did identify 1 ongoing adult RCT that compared the outcomes
of NIRS-guided CPR with current standard CPR practice (this study is anticipated to conclude in 2021)
(NCT03911908) and 2 adult SysRevs. Both adult SysRevs concluded that higher rSco2 was associated with
higher likelihood of ROSC and survival, whereas lower
rSco2 was associated with an increased mortality.90,91
There was no consensus on the predictive threshold
value of rSco2 for any outcomes.92–94 A trend of rising rSco2 (between 7% and 15% from baseline measurement) may be a more reliable predictive factor for
ROSC.90,95,96
The ScopRev also identified 2 observational studies
of NIRS in children during CPR. One found that cerebral
physiological changes were associated with changed
NIRS measurements during cardiac arrest, increased
intracranial pressure reduction, arrest resolution, and
after ROSC.97
The second small study found an association between higher minimum rSco2 during CPR and ROSC,98
but overall survival was too low to detect changes in
survival. An adult observational study found ETCO2 to
be a more accurate predictor of ROSC in OHCA.99
Task Force Insights
Survival after cardiac arrest may increase when resuscitation is tailored to the cause of the arrest and to the
patient’s responses to treatment. The level of certainty
about the use of NIRS is very low, however, and the
absence of consensus thresholds reduces its usefulness.
The value of monitoring trends in the rSco2 during pediatric resuscitation still requires validation. The PLS Task
Force agreed that given the limited evidence available,
there was currently insufficient evidence to warrant
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consideration of a SysRev. As a result, there will continue to be no treatment recommendation.
Treatment Recommendations
No treatment recommendation has been made.

Bedside Ultrasound to Identify Perfusing
Rhythm (PLS 408: ScopRev)
Rationale for Review
This topic was most recently reviewed in the 2010
CoSTR document.9,10 The PLS Task Force agreed that the
increased use of this technology warranted a ScopRev
to determine any evidence published after 2010. To review the ScopRev, see Supplement Appendix B-9.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in any setting (inhospital or out-of-hospital) with cardiac arrest
• Intervention: Point-of-care ultrasound (echocardiography during cardiac arrest)
• Comparator: Absence of point-of-care ultrasound
(echocardiography)
• Outcome: Any clinical outcome
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and all languages were
included if there was an English abstract. This literature search was updated to May 2019.
Summary of Evidence
The PLS Task Force posed 3 questions for this ScopRev:
1. Can diagnostic images be reliably obtained by
noncardiology sonographers?
2. Can reversible causes of death be identified with
high sensitivity and specificity?
3. Can the procedure be used to predict outcome?
Echocardiography typically requires pauses in chest
compressions,100–103 although the use of a protocol can
reduce the duration of these pauses.103,104 Practical difficulties in the use of ultrasound in infants and children
(that do not occur in adults) include small patient size
that may limit access to some views, particularly if other
monitoring pads are on the chest. In addition, abnormal cardiac anatomy requires advanced training if noncardiac sonographers are to derive helpful information
in this setting.
There is very limited pediatric evidence documenting
the use of ultrasonography to identify reversible causes
of arrest, for prognostication, or to determine cardiac
futility. One small series of high-risk children with ultrasound diagnosis of pulmonary emboli resulted in successful thrombolytic therapy for all, with 80% survival

Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894

Pediatric Life Support: 2020 CoSTR

to hospital discharge.105 Complete cardiac standstill as
determined sonographically is unlikely to be used as a
sign of futility during pediatric resuscitation in light of
case reports demonstrating that use of ECPR resulted
in viable cardiac function after cardiac standstill.106 Finally, significant cost is associated with the purchase of
equipment and training of users, which may limit its use
in resource-limited settings.
Task Force Insights
The PLS Task Force agreed that they would not accept
direct extrapolation from adult studies of bedside ultrasonography because there are substantial differences between adult and pediatric cardiac arrest in terms of causes,
anatomy, and technical matters—challenges that could
affect the usefulness and accuracy of the ultrasound. Although the technology is widely used within the pediatric
critical care, emergency, and resuscitation communities,
more data detailing its advantages, pitfalls, and characteristics of performance are needed so that its usefulness and
limitations in pediatric cardiac arrest can be fully defined.
In addition, there is inadequate pediatric evidence
about its intra-arrest prognostic utility, and the task
force urges great caution until more literature is available. See Supplement Appendix B-9.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
There is insufficient evidence to recommend for
or against the routine use of bedside ultrasound and
echocardiography during a pediatric arrest. Ultrasonography may be considered to identify potentially treatable causes of an arrest when appropriately skilled personnel are available, but the benefits must be carefully
weighed against the known deleterious consequences
of interrupting chest compressions.

End-Tidal CO2 Monitoring During CPR
(PLS 827: ScopRev)
Rationale for Review
The PLS Task Force initially recommended ETCO2 monitoring to confirm tracheal tube placement in 2000.59
ETCO2 monitoring can also offer an indirect indication
of cardiac output and pulmonary blood flow (noting
caveats in relation to pulmonary blood flow and ventilation: perfusion ratio or with, for example, rapid
changes caused by deterioration or response to effective treatment). As a result, ETCO2 has been proposed
as a method to evaluate the effectiveness of CPR and
to identify possible ROSC. A rapid increase in ETCO2
may be associated with improved CPR (or ROSC), and a
sustained decline or persistently low ETCO2 may be observed in the absence of ROSC. This 2020 ScopRev was
performed to identify the evidence available to support
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the use of ETCO2 to provide feedback to guide resuscitation efforts.

PALS: RESUSCITATION DRUG
ADMINISTRATION AND TIMING

Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in any setting (inhospital or out-of-hospital) with cardiac arrest
• Intervention: Presence of variables—images, cutoff values, or trends—during CPR (intra-arrest)
that can provide physiological feedback to guide
resuscitation efforts, namely ETCO2
• Comparator: The absence of such factors—
images, cut-off values, or trends
• Outcome: Any clinical outcomes
• Time frame: All years and languages were included
if there was an English abstract. This literature
search was updated to January 2020.

Drugs are used in resuscitation to support cardiovascular physiology and organ perfusion and to ameliorate
underlying pathophysiologic processes to reduce morbidity and mortality. The medication topics that were
evaluated for 2020 included the optimal ways to calculate body weight for prescribing medications dosed by
weight, amiodarone versus lidocaine for shock-resistant
VF or pVT, and the role of sodium bicarbonate and of
calcium in the management of cardiopulmonary arrest.

Summary of Evidence
The ScopRev identified only 2 pediatric observational
studies,107,108 so the search was extended to include
adult and animal literature. The latter evidence is indirect, meaning that caution is needed in extrapolating
their findings to children. To review the ScopRev, see
Supplement Appendix B-10.
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Task Force Insights
The PLS Task Force agreed that it is important to identify
measures to improve the quality of CPR. Accurate monitoring of ETCO2 during resuscitation, however, requires
the insertion of an advanced airway; advanced airway
insertion may produce undesirable effects (see Ventilation During CPR With Bag and Mask Compared With
an Advanced Airway). The 2 pediatric observational
studies identified by the ScopRev included a subset of
children in cardiac arrest, namely those who were intubated in the intensive care unit at the time of arrest.
This is a very different population from infants and children with OHCA or those who arrest in less specialized
settings such as a less well-resourced general pediatric
hospital setting or clinic.
The PLS Task Force agreed that the evidence for or
against the use of ETCO2 to guide resuscitation efforts
and improve pediatric cardiac arrest outcomes is insufficient to recommend consideration of a SysRev. As a
result, the 2015 treatment recommendation remains in
effect.11,12
Treatment Recommendations
This treatment recommendation (below) is unchanged
from the 2015.11,12
The confidence in effect estimates is so low that
the panel decided that a recommendation was too
speculative.
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Methods of Calculating Pediatric Drug
Doses (PLS 420: EvUp)
The PLS Task Force last considered this topic in 2010.9,10
The search performed for this EvUp identified multiple
publications relating to pediatric weight estimation,
considering many different methods of weight estimation. In light of the volume of pediatric publications
identified, the PLS Task Force agrees that there is sufficient evidence to consider a request for a SysRev. Until
the SysRev is completed and analyzed, the 2010 treatment recommendation remains in effect. To review the
EvUp, see Supplement Appendix C-28.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Pediatric patients with cardiac arrest
(prehospital [OHCA] or in-hospital [IHCA])
• Intervention: The use of any specific alternative
method for calculating drug dosages
• Comparator: Standard weight-based dosing
• Outcome: Achieving expected drug effect, ROSC,
survival, avoidance of toxicity
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to October 2019.
Treatment Recommendations
These treatment recommendations (below) are unchanged from 2010.9,10
To calculate the dose of resuscitation medications,
use the child’s weight if known. If the child’s weight
is unknown, it is reasonable to use a body length tape
with precalculated doses.
In nonobese pediatric patients, initial resuscitation
drug doses should be based on actual body weight
(which closely approximates ideal body weight). If necessary, body weight can be estimated from body length.
In obese patients, the initial doses of resuscitation
drugs should be based on ideal body weight that can
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be estimated from length. Administration of drug doses
based on actual body weight in obese patients may result in drug toxicity.
Subsequent doses of resuscitation drugs in both
nonobese and obese patients should take into account
the observed clinical effects and toxicities. It is reasonable to titrate the dose to the desired therapeutic effect, but it should not exceed the adult dose.

Intraosseous Versus Intravenous Route of
Drug Administration (PLS, NLS, and ALS:
SysRev)
Rationale for Review
This topic was last reviewed in 2010.9,10 A SysRev was
requested to identify evidence comparing effects of intraosseous with intravenous drug administration during
pediatric cardiac arrest. The PLS Task Force joined with the
ALS and NLS Task Forces in requesting the SysRev.
Refer to the ALS and NLS publications in this supplement for details of the evidence summary.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Pediatric patients in any setting (inhospital or out-of-hospital) with cardiac arrest
• Intervention: Placement of an intraosseous (IO)
cannula and drug administration through this IO
during cardiac arrest
• Comparator: Placement of an intravenous (IV) cannula and drug administration through this IV during cardiac arrest
• Outcome: Return of spontaneous circulation, survival to hospital discharge, and survival to hospital
discharge with a favorable neurological outcome
• Study design: Randomized trials, non-RCTs, and
observational studies (cohort studies and casecontrol studies) comparing IO with IV administration of drugs included; randomized trials assessing
the effect of specific drugs (eg, epinephrine, amiodarone/lidocaine) in subgroups related to IO versus
IV administration also included
• Time frame: All years and languages were included
if there was an English abstract; unpublished studies (eg, conference abstracts, trial protocols) were
excluded. The literature search was updated to
September 2019.
Consensus on Science
The SysRev identified no papers involving infants and
children in cardiac arrest. To review the adult evidence
identified by the SysRev, see the ALS publication in this
supplement (ALS 2046: SysRev). To review the neonatal
evidence identified by the SysRev, see the intraosseous
versus umbilical vein for emergency access discussion in
the NLS publication of this supplement (NLS 616: SysRev).
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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The PLS Task Force agreed that, in the absence of
new evidence, the previous (2010) treatment recommendation should remain in effect.9,10
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
Intraosseous cannulation is an acceptable route of vascular access in infants and children with cardiac arrest. It
should be considered early in the care of critically ill children whenever venous access is not readily available.

Epinephrine Time of Initial Dose and
Dose Interval During CPR (PLS 1541:
SysRev)
Rationale for Review
Epinephrine administration for cardiac arrest was previously reviewed in the 2015 CoSTR.11,12 The task force
reported receiving many questions about the effectiveness and timing of epinephrine administration, so they
requested a SysRev to identify any evidence published
after 2015 that could enable the formulation of a new
treatment recommendation. To review the SysRev Evidence-to-Decision Table, see Supplement Appendix
A-2.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children in cardiac arrest
(in- or out-of-hospital) (excluding resuscitation at
birth)
• Intervention: (1) Administration of the initial dose
of epinephrine earlier or later than current guideline recommendations. (2) Administration of epinephrine more or less frequently than every 3 to 5
minutes following the initial dose
• Comparator: Timing of administration of epinephrine in line with current guideline recommendations
• Outcome: Clinical outcomes, including short-term
survival and neurological outcomes (eg, hospital
discharge, 28 days, 30 days, and 1 month), and
long-term survival and neurological outcomes (eg,
3 months, 6 months, and 1 year)
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion; unpublished studies (eg, conference
abstracts, trial protocols) excluded
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to July 2019.
• International Prospective Register of Systematic
Reviews (PROSPERO) Registration: Registered
November 21, 2019. Final registration number
146531.
October 20, 2020
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Consensus on Science
We identified no pediatric RCTs on this topic. We did,
however, identify 1 observational study of pediatric
IHCA109 and 4 observational studies110 -113 of OHCA
comparing the administration of the initial dose of epinephrine earlier or later than current guideline recommendations; we also identified 2 observational studies114,115 of pediatric IHCA on the topic of administration
of epinephrine more or less frequently than every 3 to 5
minutes after the initial dose. We identified no observational studies of pediatric OHCA addressing the interval
between epinephrine doses.
Time to First Epinephrine Less Than 15 Minutes
Compared With 15 Minutes or More After Pediatric
IHCA
For the critical outcomes of survival with good neurological outcome, survival to discharge, or ROSC, we
identified 1 observational in-hospital registry study of
1558 children younger than 18 years with cardiac arrest.109 In multivariable analysis, this study provided very
low-certainty evidence (downgraded for risk of bias and
imprecision) of no benefit associated with first epinephrine dose less than 15 minutes compared with administration 15 minutes or more after cardiac arrest.
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Time to First Epinephrine Less Than 10 Minutes
Compared With 10 Minutes or More After Pediatric
IHCA
For the critical outcome of survival with good neurological outcome, we found an observational study from
the same database that identified 1395 pediatric patients younger than 18 years of age with IHCA.109 In
multivariable analysis, the study provided very low-certainty evidence (downgraded for risk of bias) of benefit
associated with time to first epinephrine dose of less
than 10 minutes compared with 10 minutes or more
after cardiac arrest (RR, 3.37; 95% CI, 1.11–10.25; 113
more per 1000; 95% CI, from 5 more to 440 more).
For the critical outcome of survival to discharge,
we identified the same observational study reporting outcomes of 1558 children with IHCA.109 After
multivariable analysis, this study provided very lowcertainty evidence (downgraded for risk of bias) of
a benefit associated with time to first epinephrine
dose of less than 10 minutes compared with 10 minutes or more after cardiac arrest (RR, 2.61; 95% CI,
1.36–5.01; 198 more per 1000; 95% CI, from 44
more to 494 more).
For the critical outcome of 24-hour survival, we
found the same observational study of 1558 children
with IHCA.109 In multivariable analysis, the study provided very low-certainty evidence (downgraded for
risk of bias) of benefit associated with time to first epinephrine dose less than 10 minutes compared with 10
minutes or more after cardiac arrest (RR, 1.58; 95%
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CI, 1.09–2.28; 178 more per 1000; 95% CI, from 28
more to 394 more).
For the critical outcome of ROSC, we found the
same study of 1558 pediatric patients with IHCA.109 In
multivariable analysis, this study provided very low-certainty evidence (downgraded for risk of bias) of benefit
associated with time to first epinephrine dose of less
than 10 minutes compared with 10 minutes or more
after cardiac arrest (RR, 1.56; 95% CI, 1.16–2.08; 233
more per 1000; 95% CI, from 66 more to 449 more).
Time to First Epinephrine Less Than 5 Minutes
Compared With 5 Minutes or More After Pediatric
IHCA
For the critical outcome of survival with good neurological outcome, we identified the same observational
study reporting on outcomes of 1395 children younger than 18 years with IHCA.109 In multivariable analysis, this study provided very low-certainty evidence
(downgraded for risk of bias) of benefit of time to first
epinephrine dose less than 5 minutes compared with
5 minutes or more after cardiac arrest (RR, 1.74; 95%
CI, 1.13–2.66; 71 more per 1000; 95% CI, from 12
more to 159 more).
For the critical outcome of survival to discharge, we
identified the same observational study of reporting on
1558 pediatric patients with IHCA.109 In multivariable
analysis, this study provided very low-certainty evidence
(downgraded for risk of bias) of benefit associated with
time to first epinephrine dose less than 5 minutes compared with 5 minutes or more after cardiac arrest (RR,
1.57; 95% CI, 1.21–2.04; 120 more per 1000; 95% CI,
from 44 more to 219 more).
For the critical outcome of 24-hour survival, we
identified the same observational study reporting on
outcomes of 1558 children with IHCA.109 In multivariable analysis, this study provided very low-certainty
evidence (downgraded for risk of bias) of benefit associated with time to first epinephrine dose less than 5
minutes compared with 5 minutes or more (RR, 1.44;
95% CI, 1.20–1.73; 153 more per 1000; 95% CI,
from 70 more to 254 more).
For the critical outcome of ROSC, we identified the
same observational study reporting on outcomes of
1558 pediatric patients with IHCA.109 In multivariable
analysis, this study provided very low-certainty evidence (downgraded for risk of bias) of benefit associated with time to first epinephrine dose less than 5
minutes compared with 5 minutes or more (RR, 1.29;
95% CI, 1.13–1.47; 149 more per 1000; 95% CI;
from 67 more to 242 more).
Time to First Epinephrine Less Than 3 Minutes
Compared With 3 Minutes or More After Pediatric
IHCA
For the critical outcome of survival with good neurological outcome, we identified 1 observational study of
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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1395 pediatric patients with IHCA.109 In multivariable
analysis, this study provided very low-certainty evidence
(downgraded for risk of bias) of benefit from time to
first epinephrine dose less than 3 minutes compared
with 3 minutes or more (RR, 1.38; 95% CI, 1.05–1.81;
48 more per 1000; 95% CI, from 6 more to 101 more).
For the critical outcome of survival to discharge, we
identified the same observational study of 1558 pediatric patients with IHCA.109 In multivariable analysis,
this study provided very low-certainty evidence (downgraded for risk of bias) of benefit associated with time
to first epinephrine dose less than 3 minutes compared
with 3 minutes or more (RR, 1.38; 95% CI, 1.17–1.63;
95 more per 1000; 95% CI, from 43 more to 158 more).
For the critical outcome of 24-hour survival, we
identified the same observational study of 1558 pediatric patients with IHCA.109 In multivariable analysis, this study provided very-low-certainty evidence
(downgraded for risk of bias) of benefit associated
with time to first epinephrine dose less than 3 minutes
compared with 3 minutes or more (RR, 1.27; 95%
CI, 1.13–1.43; 110 more per 1000; 95% CI, from 53
more to 175 more).
For the critical outcome of ROSC, we identified the
same observational study of 1558 pediatric patients
with IHCA.109 In multivariable analysis, this study provided very-low-certainty evidence (downgraded for risk
of bias) of benefit associated with time to first epinephrine dose less than 3 minutes compared with 3 minutes
or more (RR, 1.24; 95% CI, 1.13–1.35; 133 more per
1000; 95% CI, from 72 more to 195 more).
Time to First Epinephrine Less Than 15 Minutes
Compared With 15 Minutes or More After Pediatric
OHCA
For the critical outcome of survival with good neurological outcome, we identified 2 observational studies
of 725 pediatric patients 19 years or younger with traumatic (509 children)110 and nontraumatic, nonshockable (216 children)111 OHCA. These studies provided
very-low-certainty evidence (downgraded for risk of
bias, inconsistency, and imprecision), finding no benefit
associated with a first dose of epinephrine less than 15
minutes compared with 15 minutes or more (RR, 3.94;
95% CI, 0.99–15.64; 80 more per 1000; 95% CI, from
0 fewer to 397 more).
For the critical outcome of survival to discharge,
we identified 3 observational studies enrolling 27 480
children. These included emergency medical services–
treated children younger than 18 years with nonshockable arrest who did not experience ROSC within
10 minutes (26 755 children)112 and children 19 years
or younger with traumatic (509 children)110 and nontraumatic, nonshockable (216 children)111 OHCA.
These studies provided very-low-certainty evidence
(downgraded for risk of bias, inconsistency, and other
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considerations of large effect) of benefit associated
with time to first epinephrine dose less than 15 minutes compared with 15 minutes or more (RR, 2.49;
95% CI, 1.30–4.77; 28 more per 1000; 95% CI, from
6 more to 70 more).
For the critical outcome of 30-day survival, we identified 1 observational registry study of 225 children between 1 and 17 years with OHCA.113 This study provided very-low-certainty evidence (downgraded for risk
of bias, imprecision, and other considerations of very
large effect) of benefit associated with time to first epinephrine dose less than 15 minutes compared with 15
minutes or more (RR, 5.78; 95% CI, 2.82–11.86; 348
more per 1000; 95% CI, from 133 more to 791 more).
For the critical outcome of survival to intensive care
unit admission, we identified 1 observational study of
225 children 19 years or younger with nontraumatic,
nonshockable OHCA.111 This study provided very-lowcertainty evidence (downgraded for risk of bias and
imprecision) of benefit associated with time to first epinephrine dose less than 15 minutes compared with 15
minutes or more (RR, 1.96; 95% CI, 1.37–2.81; 274
more per 1000; 95% CI, from 106 more to 517 more).
For the critical outcome of ROSC, we identified 2
observational studies of 725 pediatric patients with
traumatic110 and nontraumatic, nonshockable111 OHCA.
These studies provided very-low-certainty evidence
(downgraded for risk of bias and imprecision) of benefit
associated with time to first epinephrine dose less than
15 minutes compared with 15 minutes or more (RR,
1.61; 95% CI, 1.37–1.90; 226 more per 1000; 95% CI,
from 137 more to 334 more).
Time to First Epinephrine Less Than 10 Minutes
Compared With 10 Minutes or More After Pediatric
OHCA
For the critical outcome of 30-day survival, we identified 1 observational study of 225 children between 1
and 17 years with OHCA.113 This study provided verylow-certainty evidence (downgraded for risk of bias,
imprecision, and other considerations of very large effect) of benefit associated with time to first epinephrine
dose less than 10 minutes compared with 10 minutes
or more (RR, 5.07; 95% CI, 1.20–21.42; 402 more per
1000; 95% CI, from 20 more to 1000 more).
For the critical outcome of survival to discharge, we
identified 1 observational study of 26 755 emergency
medical service–treated children younger than 18 years
with nonshockable OHCA arrest who did not experience ROSC within 10 minutes.112 This study provided
very-low-certainty evidence (downgraded for risk of
bias) of benefit with time to first epinephrine dose less
than 10 minutes compared with 10 minutes or more
(RR, 1.55; 95% CI, 1.31–1.83; 9 more per 1000; 95%
CI, from 5 more to 14 more).
October 20, 2020
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Time to First Epinephrine Less Than 5 Minutes
Compared With 5 Minutes or More After Pediatric
OHCA
For the critical outcome of survival to discharge, we
identified 1 observational study of 26 755 emergency medical services–treated children younger than 18
years with nonshockable OHCA arrest who did not experience ROSC within 10 minutes.112 This study provided very-low-certainty evidence (downgraded for risk of
bias) of benefit associated with time to first epinephrine
dose less than 5 minutes compared with 5 minutes or
more (RR, 1.81; 95% CI, 1.43–2.30; 16 more per 1000;
95% CI, from 9 more to 26 more).
Time to First Epinephrine Less Than 3 Minutes
Compared With 3 Minutes or More After Pediatric
OHCA
For the critical outcome of survival to discharge, we
identified 1 observational study of 26 755 emergency medical services–treated children younger than 18
years with nonshockable OHCA arrest who did not experience ROSC within 10 minutes.112 This study provided very-low-certainty evidence (downgraded for risk of
bias) of benefit associated with time to first epinephrine
dose less than 3 minutes compared with 3 minutes or
more (RR, 1.74; 95% CI, 1.14–2.67; 16 more per 1000;
95% CI, from 3 more to 35 more).
Downloaded from http://ahajournals.org by on June 22, 2022

Epinephrine Dose Interval of Less Than 5 Minutes
Compared With 5 Minutes or More for Pediatric IHCA
For the critical outcome of 12-month survival, we identified 1 observational study of 235 pediatric patients
with IHCA who received 2 minutes or more of chest
compressions.114
This study represented a subset of all patients with
IHCA because it enrolled only patients who were eligible for the Therapeutic Hypothermia After Pediatric
Cardiac Arrest in-hospital (THAPCA-IH) trial; the enrollees were all comatose and mechanically ventilated
after cardiac arrest, and the parents consented to enroll the children in the trial. This study provided very
low-certainty evidence (downgraded for risk of bias,
imprecision, and plausible confounding reducing demonstrated effect) of lower 12-month survival associated
with an epinephrine dose interval of less than 3 minutes (adjusted OR 0.50; 95% CI, 0.24–1.06), 5 to less
than 8 minutes (adjusted OR 0.42; 95% CI, 0.20–0.89),
or more than 8 minutes (adjusted OR 0.35; 95% CI,
0.16–0.75) compared with a 3 to less than 5-minute
dose interval.
For the critical outcome of survival to discharge,
we identified 1 observational in-hospital registry
study of 1630 children with cardiac arrest.115 This
study provided very-low-certainty evidence (downgraded for risk of bias, imprecision, and plausible
confounding suggesting spurious effect) of benefit
associated with more than 5-minute to less than
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8-minute dose intervals (adjusted OR [AOR], 1.81;
95% CI, 1.26–2.59) and 8 to less than 10-minute
intervals (AOR, 2.64; 95% CI, 1.53–4.55) compared
with dose intervals of 1 to 5 minutes.
For the critical outcome of ROSC (survival of the
IHCA event), we identified the same observational
study of 1630 children with IHCA.115 This study provided very-low-certainty evidence (downgraded for risk
of bias, imprecision, and plausible confounding suggesting spurious effect) of benefit associated with more
than 5 to less than 8 minute dose intervals (AOR, 1.71;
95% CI, 1.27–2.31) and 8 to less than 10-minute intervals (AOR, 1.93; 95% CI, 1.23–3.03) compared with
dose intervals of 1 to 5 minutes.
The same observational study of 1630 pediatric patients with IHCA included a subset analysis of 1183
children who were not receiving vasoactive infusions at
the time of arrest.115 We identified very-low-certainty
evidence (downgraded for risk of bias, imprecision,
and plausible confounding suggesting spurious effect)
of benefit associated with more than 5 to less than 8
minute dose intervals (AOR, 1.99; 95% CI, 1.29–3.06)
and 8 to less than 10-minute dose intervals (AOR, 2.67;
95% CI, 1.41–5.04) compared with dose intervals of 1
to 5 minutes.
The same observational study of 1630 pediatric
patients with IHCA included a subset analysis of 447
children who were receiving vasoactive infusions at
the time of arrest.115 We identified very-low-certainty
evidence (downgraded for risk of bias, imprecision,
and plausible confounding suggesting spurious effect)
of benefit associated with more than 5 to less than 8
minute dose intervals (AOR, 1.52; 95% CI, 0.77–3.02)
and 8 to less than 10-minute intervals (AOR, 2.62; 95%
CI, 0.85–8.07) compared with dose intervals of 1 to 5
minutes.
Epinephrine Dose Interval of Less Than 3 Minutes
Compared With 3 Minutes or More for Pediatric IHCA
For the critical outcome of 12-month survival, we
identified 1 observational study of 161 pediatric patients with IHCA who were enrolled in the THAPCAIH trial.114 This study provided very-low-certainty evidence (downgraded for risk of bias, imprecision, and
plausible confounding reducing demonstrated effect)
of harm associated with a dose interval of less than
3 minutes (AOR, 0.50; 95% CI, 0.24–1.06) as well as
5 to less than 8 minutes (AOR, 0.42; 95% CI, 0.20–
0.89) as well as 8 minutes or more (AOR, 0.5; 95%
CI, 0.16–0.75) compared with a dose interval of 3 to
less than 5 minutes.
Treatment Recommendations
We suggest that the initial dose of epinephrine in pediatric patients with nonshockable IHCA and OHCA be
administered as early in the resuscitation as possible
(weak recommendation, very low-certainty evidence).
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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We cannot make a recommendation for the timing
of the initial epinephrine dose in shockable pediatric
cardiac arrest.
The confidence of the effect estimates is so low that
we cannot make a recommendation about the optimal
interval for subsequent epinephrine doses in pediatric
patients with IHCA or OHCA.
Justification and Evidence to Decision Framework
Highlights
Time to the Initial Dose of Epinephrine
In general, observational studies can be associated with
many potential biases. Resuscitation time bias often occurs in intracardiac arrest studies such as epinephrine administration studies because the longer the duration of
the resuscitation, the lower the rate of survival. As a result, patients who received the epinephrine earlier rather
than later may have a lower mortality for reasons other
than the time of the epinephrine administration.115a This
bias can contribute to a trend toward appearance of a
harmful effect of later initial epinephrine doses. Therefore, when interpreting studies of time to the initial dose
of epinephrine, the task force considered the role of potential resuscitation time bias.
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Epinephrine Interval
Hoyme et al115 demonstrated that an increased epinephrine interval was associated with a decreased probability
of survival, with an unadjusted odds ratio for survival of
0.60 for 5 to 8 minutes between epinephrine doses and
0.62 for 8 to 10 minutes between epinephrine doses
compared with 1 to 5 minutes between epinephrine
dose. However, in the adjusted statistical model, conversely, an increased epinephrine interval was associated with an increased probability of survival. The task
force considered the fact that in the current meta-analysis, the unadjusted results, rather than the adjusted
results, were incorporated. In addition, both Hoyme et
al115 and Meert et al114 calculated the average interval
of epinephrine doses by averaging all doses within the
total arrest time; this differs from the actual interval between any 2 doses. For these reasons, the task force felt
that confidence in the estimates of effect was too low
to support a treatment recommendation regarding epinephrine dose interval. For further information, please
refer to Supplement Appendix A-2.
Knowledge Gaps
Current knowledge gaps include but are not limited to
• There is clinical equipoise and the need for pediatric randomized trials addressing the optimal timing
of initial epinephrine dose and the optimal interval
of epinephrine doses.
• Researchers must establish a consistent method
to accurately calculate/report the interval between
epinephrine doses.
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• There is a need to minimize the effects of resuscitation time bias in resuscitation clinical trials.

Amiodarone Versus Lidocaine for ShockResistant Ventricular Fibrillation or
Pulseless Ventricular Tachycardia (2018
CoSTR)
The topic of amiodarone versus lidocaine for shock-resistant VF or pVT was evaluated by the PLS Task Force in
the 2018 CoSTR Update.115b,115c Refer to those publications for details of the evidence summary and task force
considerations.
The task force agreed that a multicenter trial comparing different anti-arrhythmic agents would be helpful. Until further data are available, the 2018 treatment
recommendation remains in effect.115b,115c
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Patients of all ages (neonates, children, adolescents younger than 18 years) in any
setting with cardiac arrest and a shockable rhythm
at any time during CPR or immediately after ROSC
• Intervention: Administration (IV or IO) of an antiarrhythmic drug
• Comparator: Another anti-arrhythmic or placebo
• Outcome: Survival to hospital discharge with good
neurological outcome, survival to hospital discharge, ROSC, and rearrest after ROSC
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to August 2017.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2018.115b,115c
We suggest that amiodarone or lidocaine may be
used for the treatment of pediatric shock-resistant VF
or pVT (weak recommendation, very low-quality evidence).

Sodium Bicarbonate Administration for
Children in Cardiac Arrest (PLS 388: EvUp)
The most recent PLS Task Force review of the evidence
about sodium bicarbonate administration during cardiac arrest was in 2010.9,10 An EvUp was performed and
found insufficient evidence to consider a SysRev of this
topic, so the recommendations of 2010 remain in effect.
To review the EvUp, see Supplement Appendix C-29.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children who are in cardiac
arrest in any setting
• Intervention: Buffering agent administration
• Comparator: No use of buffering agents
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to November 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
Routine administration of sodium bicarbonate is not
recommended in the management of pediatric cardiac
arrest.

Calcium Administration in Children (PLS
421: EvUp)

Downloaded from http://ahajournals.org by on June 22, 2022

This EvUp was performed to identify any evidence published after the most recent PLS Task Force review of
this topic in 2010.9,10
The PLS Task Force agreed that there is insufficient evidence to suggest the need for a SysRev or alter the 2010
treatment recommendation, which remains in effect. To
review the EvUp, see Supplement Appendix C-30.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children who are in cardiac
arrest in any setting
• Intervention: Calcium administration
• Comparator: No calcium administration
• Outcome: All clinical outcomes
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was updated to November 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
Routine use of calcium for infants and children with
cardiopulmonary arrest is not recommended in the absence of hypocalcemia, calcium channel blocker overdose, hypermagnesemia, or hyperkalemia.
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PALS: SPECIAL RESUSCITATION
SITUATIONS—SEPTIC SHOCK,
CONGENITAL HEART DISEASE, AND
TRAUMA
This section summarizes the evidence reviews about
resuscitation of children with cardiac arrest and septic
shock, congenital heart disease such as single-ventricle
physiology, or Fontan circulation. The PLS Task Force
also reviewed the evidence about unique aspects of resuscitation after traumatic arrest.

Resuscitation of the Child With Septic
Shock (PLS 1534: EvUp)
The management of children with septic shock–associated cardiac arrest has not been previously reviewed
by the PLS Task Force. This EvUp was requested to determine the available evidence about this topic. The
EvUp identified several studies involving prevention of
cardiac arrest, but there was insufficient evidence of
unique management approaches to the children with
septic shock–associated cardiac arrest. As a result, the
task force agreed that there was no indication of a need
to consider a SysRev, and no treatment recommendation could be made at this time. To review the EvUp, see
Supplement Appendix C-31.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with sepsis in cardiac arrest
• Intervention: Specific alteration in treatment
algorithm
• Comparator: Standard care (according to 2010
treatment algorithm)
• Outcome: All
Treatment Recommendation
There is no treatment recommendation at this time.

Resuscitation of the Patient With a Single
Ventricle (PLS 390: EvUp)
This EvUp was performed to identify any evidence
published after the most recent PLS Task Force review in 2010.9,10 The EvUp identified nonrandomized
studies reporting the impact of modification to standard cardiac arrest care on outcomes in postsurgical
infants. The PLS Task Force agreed that this and additional evidence50,115d may warrant consideration for
a SysRev. Until a new SysRev is performed and analyzed by the PLS Task Force, the 2010 treatment recommendations remain in effect. To review the EvUp,
see Supplement Appendix C-32.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with single-ventricle, status/post–stage I repair who require resuscitation from cardiac arrest or prearrest states
• Intervention: Any specific modification to standard
practice
• Comparator: Standard resuscitation practice
• Outcome: ROSC, survival to discharge, survival
with good neurological outcome
• Study design: Included only observational studies and RCTs from the time of the previous search
review
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was from January 2008 to October 2019.
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Treatment Recommendations
These treatment recommendations are unchanged
from 2010.9,10
Standard resuscitation (prearrest and arrest) procedures should be followed for infants and children with
single-ventricle anatomy after stage I repair. Neonates
with a single ventricle before stage I repair who demonstrate shock caused by elevated pulmonary to systemic
flow ratio might benefit from inducing mild hypercarbia (Paco2 50–60 mm Hg); this can be achieved during
mechanical ventilation by reducing minute ventilation,
adding CO2 to inspired air, or administering opioids
with or without chemical paralysis.

Resuscitation of the Patient With HemiFontan or Fontan Circulation (PLS 392:
EvUp)
This EvUp was performed to identify any evidence
about this topic published after the PLS Task Force’s
most recent review in 2010.9,10 The EvUp identified 1
registry-based study that reported outcomes of infants
and children with Fontan/ or bidirectional Glenn who
had circulatory support initiated during a peri-arrest
phase.115d The PLS Task Force agreed that there is insufficient evidence50,115d to recommend a new SysRev, and
the 2010 treatment recommendation remains in effect,9,10 with the addition of a brief explanatory phrase
within brackets. To review the EvUp, see Supplement
Appendix C-33.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with Fontan or
hemi-Fontan or bidirectional Glenn circulation
who require resuscitation from cardiac arrest or
prearrest states (prehospital or in-hospital)
• Intervention: Specific modification to standard
resuscitation practice
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894

Pediatric Life Support: 2020 CoSTR

• Comparator: Standard resuscitation practice
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages were included
if there was an English abstract. The literature
search was from January 2013 to September 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010 with the exception of limiting the recommendation to children with hemi-Fontan9,10 or bidirectional Glenn physiology who are in a prearrest state;
hypercarbia achieved by hypoventilation may be beneficial to increase oxygenation and cardiac output.
Negative-pressure ventilation, if available, may be
beneficial for children with either hemi-Fontan or bidirectional Glenn or Fontan physiology by increasing
cardiac output.
During cardiopulmonary arrest, it is reasonable to
consider ECPR for patients with Fontan physiology.
There is insufficient evidence to support or refute the
use of ECPR in patients with hemi-Fontan or bidirectional Glenn physiology.

Resuscitation After Traumatic Arrest (PLS
498: EvUp)
An EvUp was performed to identify any relevant studies
published in the decade after the 2010 PLS Task Force
review of the topic.9,10 The PLS Task Force agreed that
the evidence warrants consideration of a SysRev, preferably one including not only adults but also infants
and children in the study population, to determine the
evidence to support specific recommendations about
resuscitation for traumatic cardiac arrest. To review the
EvUp, see Supplement Appendix C-34.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children with major (blunt
or penetrating) injury in cardiac arrest in any setting
• Intervention: Any specific alteration in treatment
algorithm
• Comparator: Standard care (according to 2010
treatment algorithm)
• Outcome: All
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages included if
there was an English abstract; literature search was
updated to December 2019.
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Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2010.9,10
There is insufficient evidence to make a recommendation for modification of standard resuscitation for
infants and children experiencing cardiac arrest due to
major trauma, although consideration should be given
to selectively performing a resuscitative thoracotomy in
children with penetrating injuries who arrive at the hospital with a perfusing rhythm.

PALS: POST–CARDIAC ARREST
CARE, INCLUDING POSTARREST
PROGNOSTICATION
Targeted Temperature Management
(2019 CoSTR)
A SysRev addressing targeted temperature management (TTM) was published in 2019,116 and an ILCOR Pediatric CoSTR was published as part of the 2019 CoSTR
summary.71,72 Refer to those publications for details of
the evidence summary and task force considerations.
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Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Pediatric patients (more than 24 hours
to 18 years of age) who achieved ROSC after
OHCA or IHCA
• Intervention: TTM with a target temperature of
32°C to 36°C
• Comparator: No TTM or TTM at an alternative target temperature range
• Outcome:
– Primary outcome: Good neurobehavioral survival long term
– Secondary outcomes:
○ Good neurobehavioral survival short term and
intermediate term
○ Survival short term, intermediate term, and
long term
○ Neurobehavioral score changes from prearrest, intermediate term, and long term
○ Health-related quality of life score intermediate term and long term
○ Health-related quality of life score change
from prearrest, intermediate term, and long
term
– Additional in-hospital adverse outcomes:
○ Infection (culture proven)
○ Recurrent cardiac arrest (not leading to death)
○ Serious bleeding (red blood cell transfusion)
○ Arrhythmias (any)
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
S174 October 20, 2020
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before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages included if
there was an English abstract; literature search was
updated to December 2018.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2019 (with the exception of the addition of text to
clarify that recommendations apply to children who remain comatose after OHCA or IHCA and to clarify that
the temperature should be maintained 37.5°C or less).
We suggest that for infants and children who remain
comatose following ROSC from OHCA and IHCA, TTM
be used to maintain a central temperature of 37.5°C or
less (weak recommendation, moderate-certainty evidence).
On the basis of 2 randomized trials and 8 retrospective observational cohort studies that provided comparative data on favorable neurological outcome, survival,
and in-hospital adverse events, there is inconclusive
evidence to support or refute the use of TTM 32°C to
34°C compared with TTM 36°C to 37.5°C (or an alternative temperature) for children who achieve ROSC but
remain comatose after OHCA or IHCA.

Oxygen and Carbon Dioxide Targets
in Pediatric Patients With Return of
Spontaneous Circulation After Cardiac
Arrest (PLS 815: SysRev)
A SysRev of arterial oxygen and carbon dioxide targets
in adults and children with ROSC after cardiac arrest,116a
was conducted with involvement of clinical content experts from the ALS and PLS Task Forces. Evidence from
adult and pediatric literature was sought and considered by the ALS and PLS Task Forces, respectively. This
CoSTR focuses on evidence derived from infants and
children. See Supplement Appendix A-3 for more details.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Unresponsive children with sustained
return of spontaneous circulation (ROSC) after cardiac arrest in any setting
• Intervention: A ventilation strategy targeting specific Spo2 [oxygen saturation], Pao2 [partial pressure
of oxygen], and/or Paco2 [partial pressure of carbon dioxide] targets
• Comparator: Treatment without specific targets or
with an alternate target to the intervention
• Outcome: Clinical outcome including survival/
survival with a favorable neurological outcome at
hospital discharge/30 days, and survival/survival
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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with a favorable neurological outcome after hospital discharge/30 days (eg, 90 days, 180 days, 1
year)
• Study design: Randomized trials, non-RCTs, and
observational studies (cohort studies and casecontrol studies) with a control group (ie, patients
treated with no specific Spo2, Pao2, and/or Paco2
targets or an alternative target to the intervention)
included
• Time frame: All years and languages included; literature search was updated to August 2019.
Consensus on Science
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Oxygen Targets
We identified no pediatric RCTs on this topic but did
identify 2 observational studies published in the 5
years after the previous (201511,12) review.117,118 One
of these118 was deemed at critical risk of bias for lack
of adjustment for cardiac arrest characteristics; for this
reason, interpretation of these results is severely limited. Within these limitations, this study included 253
patients and found no association between hyperoxemia and clinical outcomes in adjusted analyses (numeric
adjusted results not reported). Of all studies identified
(including those reviewed in 201511,12), only 3 pediatric
studies,117,119,120 including a total of 618 patients, were
deemed to have only serious risk of bias, and in all of
these studies only adjusted results were reported.
For the critical outcome of survival to hospital discharge with good neurological outcome, we identified
1 observational study of 153 pediatric patients with
ROSC after cardiac arrest.120 This study provided verylow-certainty evidence (downgraded for indirectness,
imprecision, and risk of bias), finding no benefit of hyperoxemia compared with no hyperoxemia (OR, 1.02;
95% CI, 0.46–2.27; 5 more per 1000; 95% CI, from
170 fewer to 202 more).
For the critical outcome of survival to hospital discharge, we identified 1 observational study of 164 pediatric patients with ROSC after IHCA119 providing very
low-certainty evidence (downgraded for indirectness,
imprecision, and very serious risk of bias) comparing
hyperoxemia with normoxemia and finding no benefit
to hyperoxemia, although numeric results of adjusted
analyses were not reported. We identified a second
study of 200 pediatric patients with ROSC after cardiac arrest117 that provided very low-certainty evidence
(downgraded for indirectness, imprecision, and serious
risk of bias) and that showed no association of postROSC Pao2 greater than 200 mm Hg with outcome (OR
0.81; 95% CI, 0.41–1.59; absolute risk difference not
calculable because the number of survivors in the normoxemia group was not reported).
One large registry-based study121 found that hyperoxemia was associated with higher mortality when compared
with normoxemia. Although this study was much larger
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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than the others, it was deemed at critical risk of bias as a
result of lack of adjustment for cardiac arrest characteristics (increasing the risk of confounding) and the exclusion
of the 31% of all eligible patients who lacked an arterial
blood gas analysis within 1 hour of ROSC. The task force
thought that this exclusion increased risk of selection bias
because patients who did not have an arterial blood gas
analysis within 1 hour of ROSC are likely disproportionally
normoxemic or hyperoxemic rather than hypoxemic.
Carbon Dioxide Targets
We identified no pediatric RCTs on this topic. Two observational studies were identified,118,119 1 of which118
was published in the interval after the search was completed for the 2015 CoSTR. Only adjusted results from
these studies were reported. One study119 including 223
patients provided very-low-certainty evidence (downgraded for risk of bias and indirectness) of an increase
in hospital mortality associated with both hypocapnia
(OR, 2.71; 95% CI, 1.04–7.05; 242 more per 1000;
95% CI, from 9 more to 446 more) and hypercapnia
after ROSC (OR, 3.27; 95% CI, 1.62–6.61; 286 more
per 1000; 95% CI, from 114 more to 423 more). The 1
study published after the 2015 review118 was deemed at
critical risk of bias for lack of adjustment for cardiac arrest characteristics. Within these limitations, this study
included 253 patients and found an increase in hospital
mortality associated with both hypocapnia compared
with normocapnia (OR, 2.62; 95% CI, 1.08–6.4; 233
more per 1000; 95% CI, from 17 more to 429 more)
and hypercapnia compared with normocapnia (OR, 2.0;
95% CI, 1.01–3.97; 166 more per 1000; 95% CI, from
2 more to 332 more) 1 hour after ROSC.
The available evidence on the effect of hypercapnia
or hypocapnia in adults is inconsistent, with the randomized trials done to date showing no effect.
Treatment Recommendations
We suggest that rescuers measure Pao2 after ROSC and
target a value appropriate to the specific patient condition. In the absence of specific patient data, we suggest
rescuers target normoxemia after ROSC (weak recommendation, very low-quality evidence).*
Given the availability of continuous pulse oximetry,
targeting an oxygen saturation of 94% to 99% may be
a reasonable alternative to measuring Pao2 for titrating
oxygen when feasible to achieve normoxia (based on
expert opinion).
We suggest that rescuers measure Paco2 after ROSC
and target normocapnia (weak recommendation, very
low-certainty evidence).
*Note: This treatment recommendation applies to infants 28 days to 12
months and children in cardiac arrest. For recommendations applying
to newborns resuscitated at birth, refer to “Neonatal Life Support:
2020 International Consensus on CPR and ECC Science With Treatment
Recommendations”7a,7b in this supplement.
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Consider adjustments to the target Paco2 for specific
patient populations where normocapnia may not be desirable (eg, chronic lung disease with chronic hypercapnia,
congenital heart disease with single-ventricle physiology,
increased intracranial pressure with impending herniation).
Justification and Evidence to Decision Framework
Highlights
Measurement of the arterial Pao2 and Paco2 is much
easier to perform in the hospital than in the out-ofhospital setting. Yet without such monitoring in the
out-of-hospital setting, it will be difficult for providers
to judge within tolerable ranges the balance between
hypoxemia and hyperoxemia and between overventilation and underventilation. These ranges of appropriate
Pao2 and Paco2 will also differ for some patients, such as
those with cyanotic congenital heart disease.
In steady state situations (eg, steady temperature,
Paco2, and pH), providers may be able to correlate the
Paco2 with the ETCO2 to determine trends that may
provide information about ongoing ventilatory responses to support ventilation.
The PLS Task Force recognized the paucity of data
available to make recommendations about target values
for Pao2 and Paco2 in infants and children after ROSC.
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Oxygen Targets
Accurate targeting of post-ROSC normoxemia might be
achievable and acceptable being guided by pulse oximetry in the hospital setting, but the use of pulse oximetry
to titrate oxygen administration to target normoxemia in
the out-of-hospital setting has not been studied and is
not without risk of inadvertent patient hypoxemia. Given
the known risks of hypoxemia and the uncertain risks
of hyperoxia, any titration of oxygen delivery to children
after ROSC must be balanced against the risk of inadvertent hypoxemia stemming from overzealous weaning of
Fio2. Further challenges include identifying the appropriate targets for specific pediatric patient subpopulations
(eg, infants and children with cyanotic heart disease).
Carbon Dioxide Targets
Accurate targeting of post-ROSC normocapnia might
be achievable and acceptable in the in-hospital critical
care setting. Serial assessment of ventilation through
arterial blood gas analysis is facilitated by arterial catherization, which may also be beneficial for targeting
post-ROSC blood pressure targets. Correlation of Paco2
and ETCO2 may allow ongoing monitoring of ventilation when continuous capnography is available. Further challenges include identifying any modified Paco2
targets needed for specific pediatric patient subpopulations (eg, infants and children with suspected increased intracranial pressure).
For further information about task force development of treatment recommendations from the
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published evidence on this topic, see the evidence-todecision table in Supplement Appendix A-3.
Knowledge Gaps
The PLS Task Force identified the following knowledge
gaps:
• There are no pediatric randomized trials comparing oxygen or carbon dioxide management strategies in post–cardiac arrest care.
• We found no published evidence to determine
how Paco2 targets should be adjusted in infants
and children with chronic CO2 retention.
• We found no published evidence to determine
whether adjusting arterial blood gas analysis
to 37°C or to a patient’s current temperature is
beneficial.

Post-ROSC Blood Pressure Control (PLS
820: EvUp)
This topic was most recently reviewed in 2015.11,12
This EvUp was performed to identify new evidence
published in the most recent 5 years. The EvUp identified evidence to suggest that post–cardiac arrest hypotension below the fifth percentile for age is associated
with poorer outcomes when compared with post–cardiac arrest normotension, and those patients requiring
higher inotropic drug support have lower rates of survival to hospital discharge. The task force agreed that
the EvUp identified sufficient new evidence to suggest
the need for a SysRev. Until such time as a SysRev is
completed and evaluated, the 2015 treatment recommendations remain in effect.11,12 To review the EvUps,
see Supplement Appendix C-35 and Supplement Appendix C-36.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children after ROSC
• Intervention: Use of parenteral fluids and inotropes and/or vasopressors to maintain targeted measures of perfusion such as blood pressure
• Comparator: No use of these interventions
• Outcome: Patient satisfaction; survival with favorable neurological and functional outcome at discharge, 30 days, 60 days, 180 days, and/or 1 year;
survival with favorable neurological and functional
outcome at discharge, 30 days, 60 days, 180 days,
and/or 1 year; survival to hospital discharge; harm
to patient
• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
Circulation. 2020;142(suppl 1):S140–S184. DOI: 10.1161/CIR.0000000000000894
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• Time frame: All years and languages included if
there was an English abstract; literature search was
updated to September 2019.
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2015.11,12
We recommend that for infants and children after ROSC, parenteral fluids and/or inotropes or vasopressors should be used to maintain a systolic blood
pressure of at least greater than the fifth percentile
for age (strong recommendation, very low-quality
evidence).

Post-ROSC Neuroprognostication and Use
of Electroencephalogram (PLS 813 and
PLS 822: EvUp)
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The most recent PLS Task Force review of post-ROSC
predictive factors was published in the 2015 CoSTR but
was focused only on the use of electroencephalography.11,12 This EvUp was performed to determine if sufficient evidence exists to suggest the need for a SysRev.
The EvUp identified 8 studies reporting associations of
several factors in addition to electroencephalography
with outcomes after cardiac arrest.
The PLS Task Force agreed that this topic is of such
interest that they support the suggestion of a SysRev,
with a broader search strategy to include studies of
additional potential prognostic indicators beyond the
electroencephalography. Until the SysRev is completed, the 2015 treatment recommendation remains in
effect.11,12 To review the EvUp, see Supplement Appendix C-37.
Population, Intervention, Comparator, Outcome,
Study Design, and Time Frame
• Population: Infants and children who have had
cardiac arrests in the hospital or out-of-hospital
setting
• Intervention: Use of neuro-electrophysiology information (electroencephalography). Note: the PLS
Task Force agreed that the list of possible interventions or diagnostic tools must expand for the next
search.
• Comparator: None
• Outcome: Survival to 1 year with good neurological outcome, survival to 180 days with good
neurological outcome, survival to 60 days with
good neurological outcome, survival to 6 months,
survival to 30 days with good neurological outcome, survival to 30 days with good neurological
outcome, survival to hospital discharge with good
neurological outcome, survival with favorable neurological outcome, survival to hospital discharge
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• Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled
before-and-after studies, cohort studies) eligible
for inclusion
• Time frame: All years and languages included if
there was an English abstract; literature search
from January 2013 to August 2019
Treatment Recommendations
This treatment recommendation (below) is unchanged
from 2015.11,12
We suggest that practitioners use multiple variables
when attempting to predict outcomes for infants and
children after cardiac arrest (weak recommendation,
very low-quality evidence).

TOPICS NOT REVIEWED IN 2020
• Etomidate and pediatric septic shock (PLS 402)
• Compression-only CPR for intubated neonates
outside delivery room (PLS 380)
• Formulas for peds endotracheal tube size (PLS 401)
• Endotracheal tube versus IV drugs (PLS 403)

FUTURE TASKS
The following PICOSTs were prioritized by the task
force for performing a SysRev. The PLS Task Force will
determine the time-tabling for this body of work.
Fluid administration for septic shock (PLS New)
Fluid administration in shock associated with dengue
Fluid administration in malaria with shock
Optimal timing for the administration of fluid resuscitation in pediatric trauma
Prearrest care of the infant or child with dilated cardiomyopathy or myocarditis (PLS 819: EvUp)
Prevention and management of pulmonary hypertensive crisis in infants and children (PLS 391: EvUp)
Opioids, sedatives, and muscle relaxants for pulmonary hypertension (PLS 056: EvUp)
Therapy with inhaled nitric oxide or prostaglandin I2
for pulmonary hypertensive crisis and right heart failure
(2020 New EvUp)
CPR for heart rate of less than 60/min (PLS 1535:
EvUp)
Energy doses for defibrillation (PLS 405: ScopRev)
Advanced airways: Cuffed versus uncuffed tubes
(PLS 412: EvUp)
Resuscitation of the patient with a single ventricle
(PLS 390: EvUp)
Resuscitation after traumatic arrest (PLS 498: EvUp)
Post-ROSC blood pressure control (PLS 820: EvUp)
Further work will be undertaken to look at diagnostic
tests (PLS 411)
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Effect of identification and preventive management
of genetically related family members of those with
channelopathies on incidence of cardiac arrest (PLS 417)

This article has been copublished in Resuscitation. Published by Elsevier Ireland Ltd. All rights reserved. This article has been reprinted in Pediatrics.
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